

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40, C07D 207/08, 207/12	A1	(11) International Publication Number: WO 98/29117 (43) International Publication Date: 9 July 1998 (09.07.98)
(21) International Application Number: PCT/US97/24070 (22) International Filing Date: 23 December 1997 (23.12.97) (30) Priority Data: 08/775,585 31 December 1996 (31.12.96) US Not furnished 23 December 1997 (23.12.97) US (71) Applicant: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US). (72) Inventors: HAMILTON, Gregory, S.; 6501 Frederick Road, Catonsville, MD 21228 (US). LI, Jia-He; 27 Warren Manor Court, Cockeysville, MD 21030 (US). HUANG, Wei; Apartment D, 910 Hooper Avenue, Baltimore, MD 21229 (US). (74) Agent: NATH, Gary, M.; Nath & Associates, Suite 750, 1835 K Street, N.W., Washington, DC 20006-1203 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS (57) Abstract This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

N-LINKED UREAS AND CARBAMATES OF
HETEROCYCLIC THIOESTERS

This application is a continuation-in-part
5 application of U.S. Patent Application Serial No.
08/775,535 filed December 31, 1996.

BACKGROUND OF THE INVENTION

1. Field of Invention

10 This invention relates to neurotrophic low
molecular weight, small molecule N-linked ureas and
carbamates of heterocyclic thioesters having an
affinity for FKBP-type immunophilins, and their use as
inhibitors of the enzyme activity associated with
15 immunophilin proteins, particularly peptidyl-prolyl
isomerase, or rotamase, enzyme activity.

2. Description of Related Art

The term immunophilin refers to a number of
proteins that serve as receptors for the principal
20 immunosuppressant drugs, cyclosporin A (CsA), FK506
and rapamycin. Known classes of immunophilins are
cyclophilins and FK506 binding proteins, or FKBP's.
Cyclosporin A binds to cyclophilin A while FK506 and
rapamycin bind to FKBP12. These immunophilin-drug
25 complexes interface with various intracellular signal
transduction systems, especially the immune and
nervous systems.

Immunophilins are known to have peptidyl-prolyl

isomerase (PPIase), or rotamase, enzyme activity. It has been determined that rotamase enzyme activity plays a role in the catalyzation of the interconversion of the cis and trans isomers of peptide and protein substrates for the immunophilin proteins.

Immunophilins were originally discovered and studied in the immune tissue. It was initially postulated by those skilled in the art that inhibition of the immunophilins' rotamase activity leads to inhibition of T-cell proliferation, thereby causing the immunosuppressive activity exhibited by immunosuppressant drugs, such as cyclosporin A, FK506 and rapamycin. Further study has shown that the inhibition of rotamase activity, in and of itself, does not result in immunosuppressive activity. Schreiber et al., Science, 1990, vol. 250, pp. 556-559. Instead, immunosuppression appears to stem from the formulation of a complex of immunosuppressant drugs and immunophilins. It has been shown that the immunophilin-drug complexes interact with ternary protein targets as their mode of action. Schreiber et al., Cell, 1991, vol. 66, pp. 807-815. In the case of FKBP-FK506 and cyclophilin-CsA, the immunophilin-drug complexes bind to the enzyme calcineurin and inhibit the T-cell receptor signalling which leads to T-cell

proliferation. Similarly, the immunophilin-drug complex of FKBP-rapamycin interacts with the RAFT1/FRAP protein and inhibits the IL-2 receptor signalling.

5 Immunophilins have been found to be present at high concentrations in the central nervous system. Immunophilins are enriched 10-50 times more in the central nervous system than in the immune system. Within neural tissues, immunophilins appear to
10 influence nitric oxide synthesis, neurotransmitter release and neuronal process extension.

 It has been found that picomolar concentrations of an immunosuppressant such as FK506 and rapamycin stimulate neurite outgrowth in PC12 cells and sensory
15 neurons, namely dorsal root ganglion cells (DRGs). Lyons et al., *Proc. of Natl. Acad. Sci.*, 1994, vol. 91, pp. 3191-3195. In whole animal experiments, FK506 has been shown to stimulate nerve regeneration following facial nerve injury.

20 Surprisingly, it has been found that certain compounds with a high affinity for FKBP are potent rotamase inhibitors and exhibit excellent neurotrophic effects. Furthermore, these rotamase inhibitors are devoid of immunosuppressive activity. These findings
25 suggest the use of rotamase inhibitors in treating various peripheral neuropathies and enhancing neuronal

regrowth in the central nervous system (CNS). Studies have demonstrated that neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) may occur due to
5 the loss, or decreased availability, of a neurotrophic substance specific for a particular population of neurons affected in the disorder.

Several neurotrophic factors affecting specific neuronal populations in the central nervous system
10 have been identified. For example, it has been hypothesized that Alzheimer's disease results from a decrease or loss of nerve growth factor (NGF). It has thus been proposed to treat Senile Dementia of the Alzheimer's Type (SDAT) patients with exogenous nerve
15 growth factor or other neurotrophic proteins, such as brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor and neurotrophin-3, to increase the survival of degenerating neuronal populations.

20 Clinical application of these proteins in various neurological disease states is hampered by difficulties in the delivery and bioavailability of large proteins to nervous system targets. By contrast, immunosuppressant drugs with neurotrophic
25 activity are relatively small and display excellent bioavailability and specificity. However, when


administered chronically, immunosuppressant drugs exhibit a number of potentially serious side effects including nephrotoxicity, such as impairment of glomerular filtration and irreversible interstitial fibrosis (Kopp et al., *J. Am. Soc. Nephrol.*, 1991, 1:162); neurological deficits, such as involuntary tremors, or non-specific cerebral angina, such as non-localized headaches (De Groen et al., *N. Engl. J. Med.*, 1987, 317:861); and vascular hypertension with complications resulting therefrom (Kahan et al., *N. Engl. J. Med.*, 1989, 321:1725).

In order to prevent the side effects associated with use of the immunosuppressant compounds, the present invention provides non-immunosuppressive compounds containing small molecule FKBP rotamase inhibitors for enhancing neurite outgrowth, and promoting neuronal growth and regeneration in various neuropathological situations where neuronal repair can be facilitated, including: peripheral nerve damage caused by physical injury or disease state such as diabetes; physical damage to the central nervous system (spinal cord and brain); brain damage associated with stroke; and neurological disorders relating to neurodegeneration, such as Parkinson's disease, SDAT (Alzheimer's disease), and amyotrophic lateral sclerosis.

SUMMARY OF THE INVENTION

The present invention relates to neurotrophic, low molecular weight, small molecule compounds having an affinity for FKBP-type immunophilins. Once bound to these proteins, the neurotrophic compounds are potent inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity. A key feature of the compounds of the present invention is that they do not exert any significant immunosuppressive activity in addition to their neurotrophic activity. Another significant feature is the novel addition of a thioester linkage and an unexpected increase in bioavailability and potency as compared to compounds lacking a thioester linkage.

Specifically, the present invention relates to a compound of formula I:



or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A and B are taken together with the nitrogen and carbon atoms to which they are respectively attached

to form a 5-7 membered saturated or unsaturated heterocyclic ring containing any combination of CH_2 , O, S, SO, SO_2 , NH or NR_1 ;

X is either O or S;

5

Y is a direct bond to Z, a $\text{C}_1\text{-C}_4$ straight or branched chain alkyl, or a $\text{C}_1\text{-C}_4$ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR_1 , S, SO, or SO_2 , wherein R_1 is selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_4)$ -straight or branched chain alkyl, $(\text{C}_1\text{-C}_4)$ -straight or branched chain alkenyl or alkynyl, and $(\text{C}_1\text{-C}_4)$ bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

10
15
20

25

Z is a direct bond, or a $\text{C}_1\text{-C}_4$ straight or branched chain alkyl, or a $\text{C}_1\text{-C}_4$ straight or branched

chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₂, S, SO, or SO₂, wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:

hydrogen, Ar, C₁-C₄ straight or branched chain alkyl, or C₁-C₄ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more position(s) with C₁-C₄ cycloalkyl, C₁-C₄ cycloalkenyl, hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups are optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,

hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminocalkyl, sulfhydryl, thioalkyl, sulfonyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

wherein Ar is an aryl or heteroaryl moiety which is substituted or unsubstituted;

W is oxygen or sulfur;

U is either O or N, wherein when U is O, then R₁ is a lone pair of electrons and R₂ is selected from the group consisting of:

Ar as defined above, C₁-C₄ cycloalkyl, C₁-C₄ straight or branched chain alkyl or alkenyl, or C₁-C₄ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino,

halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄,
straight or branched chain alkyl, C₂-C₄, straight or
branched chain alkenyl, carbonyl, thiocarbonyl, ester,
thioester, alkoxy, alkenoxy, cyano, nitro, imino,
5 alkylamino, aminocalkyl, sulfhydryl, thioalkyl,
sulfonyl, substituted alkyl or alkenyl wherein any of
the carbon atoms of the alkyl or alkenyl are
optionally replaced with S, SO, SO₂, O, or NR₁ wherein
R₁ is selected from the group consisting of hydrogen,
10 (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-
straight or branched chain alkenyl or alkynyl, and (C₁-
C₄) bridging alkyl wherein said bridging alkyl forms a
heterocyclic ring starting with the nitrogen of NR₁ and
ending with one of the carbon atoms of said alkyl or
15 alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group or C₁-C₄ cycloalkyl;

and when U is N, R₁ and R₂ are selected
independently from the group consisting of:

hydrogen, Ar as defined above, C₁-C₄ cycloalkyl,
20 C₁-C₄, straight or branched chain alkyl or alkenyl, or
C₁-C₄, straight or branched chain alkyl or alkenyl
substituted in one or more positions with Ar, amino,
halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄,
straight or branched chain alkyl, C₂-C₄, straight or
25 branched chain alkenyl, carbonyl, thiocarbonyl, ester,
thioester, alkoxy, alkenoxy, cyano, nitro, imino,

alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SO, SO₂, O, or NR₂ wherein
5 R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and
10 ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or C₁-C₄ cycloalkyl;

or R₁ and R₂ may be taken together to form a heterocyclic ring.

15 In preferred embodiments, Ar is a cyclic or fused cyclic ring and includes a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to five position(s) with halo, haloalkyl, hydroxyl, nitro,
20 trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₁-C₄ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₁-C₄ alkenyloxy, phenoxy, benzyloxy, amino, thiocarbonyl, ester, thioester, cyano, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, and
25 sulfonyl; wherein the individual ring sizes are 5-6 members; wherein the heterocyclic ring contains 1-4

are CH_2 ;

X is either O or S;

Y is a direct bond to Z, a $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, or a $\text{C}_1\text{-C}_6$ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH , NR_1 , S, SO, or SO_2 , wherein R_1 is selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkyl, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkenyl or alkynyl, and $(\text{C}_1\text{-C}_6)$ bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

Z is a direct bond, or a $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, or a $\text{C}_1\text{-C}_6$ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl,

thiocarbonyl, ester, thioester, alkoxy, alkenoxy,
cyano, nitro, imino, alkylamino, aminoalkyl,
sulfhydryl, thioalkyl, sulfonyl, oxygen to form a
carbonyl, or wherein any of the carbon atoms of said
5 alkyl or alkenyl are optionally replaced with O, NH,
NR₂, S, SO, or SO₂, wherein R₂ is selected from the
group consisting of hydrogen, (C₁-C₄)-straight or
branched chain alkyl, (C₁-C₄)-straight or branched
chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl
10 wherein said bridging alkyl forms a heterocyclic ring
starting with the nitrogen of NR₂ and ending with one
of the carbon atoms of said alkyl or alkenyl chain,
and wherein said heterocyclic ring is optionally fused
to an Ar group;

15 C and D are independently:

hydrogen, Ar, C₁-C₄ straight or branched chain
alkyl, or C₁-C₄ straight or branched chain alkenyl,
wherein any of the carbon atoms of said alkyl or
alkenyl are optionally substituted in one or more
20 position(s) with C₁-C₄ cycloalkyl, C₁-C₄ cycloalkenyl,
hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl,
alkenyl, cycloalkyl or cycloalkenyl groups are
optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,
hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester,
25 thioester, alkoxy, alkenoxy, cyano, nitro, imino,
alkylamino, aminoalkyl, sulfhydryl, thioalkyl,

sulfonyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group; wherein Ar is an aryl or heteroaryl moiety which is substituted or unsubstituted;

W is oxygen or sulfur;

U is either O or N, wherein when U is O, then R₂ is a lone pair of electrons and R₃ is selected from the group consisting of:

Ar as defined above, C₁-C₄ cycloalkyl, C₁-C₄ straight or branched chain alkyl or alkenyl, or C₁-C₄ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₁-C₄ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester,

thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are
5 optionally replaced with S, SO, SO₂, O, or NR₂ wherein R₂ is selected from the group consisting of hydrogen; (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a
10 heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or C₁-C₄ cycloalkyl;

and when U is N, R₁ and R₂ are selected
15 independently from the group consisting of:

hydrogen, Ar as defined above, C₁-C₄ cycloalkyl, C₁-C₄ straight or branched chain alkyl or alkenyl, or C₁-C₄ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₁-C₄ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of
25 the carbon atoms of the alkyl or alkenyl are

optionally replaced with S, SO, SO₂, O, or NR₂ wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or C₁-C₄ cycloalkyl;


10 or R₁ and R₂ may be taken together to form a heterocyclic ring.

In preferred embodiments, Ar is a cyclic or fused cyclic ring and includes a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is
15 either unsubstituted or substituted in one to five position(s) with halo, haloalkyl, hydroxyl, nitro, trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₁-C₄ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₁-C₄ alkenyloxy, phenoxy, benzyloxy, amino,
20 thiocarbonyl, ester, thioester, cyano, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, and sulfonyl; wherein the individual ring sizes are 5-8 members; wherein the heterocyclic ring contains 1-4 heteroatom(s) selected from the group consisting of O,
25 N, or S; wherein aromatic or tertiary alkyl amines are optionally oxidized to a corresponding N-oxide.

Particularly preferred Ar groups include phenyl, benzyl, naphthyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, and thienyl.

Preferred heterocyclic groups may be selected from the group consisting of pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, thienyl, piperidinyl, and piperazinyl.

Another preferred embodiment is a compound of formula III:



III

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

E, F, and G are independently CH_2 , O, S, SO, SO_2 , NH or NR , wherein at least 2 of E, F, and G are CH_2 ;

X is either O or S;

Y is a direct bond to Z, a C_1 - C_4 straight or branched chain alkyl, or a C_1 - C_4 straight or branched

chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NR, NR₂, S, SO, or SO₂, wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

Z is a direct bond, or a C₁-C₄ straight or branched chain alkyl, or a C₁-C₄ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said

alkyl or alkenyl are optionally replaced with O, NH, NR₂, S, SO, or SO₂, wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₃)-straight or branched chain alkyl, (C₁-C₃)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:

hydrogen, Ar, C₁-C₃ straight or branched chain alkyl, or C₁-C₃ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more position(s) with C₁-C₃ cycloalkyl, C₁-C₃ cycloalkenyl, hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups are optionally substituted with C₁-C₃ alkyl, C₁-C₃ alkenyl, hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or

alkenyl are optionally replaced with O, NH, NR₁, S, SO,
or SO₂, wherein R₁ is selected from the group
consisting of hydrogen, (C₁-C₄)-straight or branched
chain alkyl, (C₁-C₄)-straight or branched chain alkenyl
5 or alkynyl, and (C₁-C₄) bridging alkyl wherein said
bridging alkyl forms a heterocyclic ring starting with
the nitrogen of NR₁ and ending with one of the carbon
atoms of said alkyl or alkenyl chain, and wherein said
heterocyclic ring is optionally fused to an Ar group;
10 wherein Ar is an aryl or heteroaryl moiety which
is substituted or unsubstituted;

W is oxygen or sulfur;

U is either O or N, wherein when U is O, then R₁
is a lone pair of electrons and R₂ is selected from the
15 group consisting of:

Ar as defined above, C₁-C₄ cycloalkyl, C₁-C₄
straight or branched chain alkyl or alkenyl, or C₁-C₄
straight or branched chain alkyl or alkenyl
substituted in one or more positions with Ar, amino,
0 halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄
straight or branched chain alkyl, C₁-C₄ straight or
branched chain alkenyl, carbonyl, thiocarbonyl, ester,
thioester, alkoxy, alkenoxy, cyano, nitro, imino,
alkylamino, aminoalkyl, sulfhydryl, thioalkyl,
25 sulfonyl, substituted alkyl or alkenyl wherein any of
the carbon atoms of the alkyl or alkenyl are

optionally replaced with S, SO, SO₂, O, or NR₂ wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or C₁-C₄ cycloalkyl;

10 and when U is N, R₁ and R₂ are selected independently from the group consisting of:

hydrogen, Ar as defined above, C₁-C₄ cycloalkyl, C₁-C₄ straight or branched chain alkyl or alkenyl, or C₁-C₄ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₁-C₄ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SO, SO₂, O, or NR₂ wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-

15

20

25

C₁) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or C₁-C₃ cycloalkyl;

or R₁ and R₂ may be taken together to form a heterocyclic ring.


In preferred embodiments, Ar is a cyclic or fused cyclic ring and includes a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to five position(s) with halo, haloalkyl, hydroxyl, nitro, trifluoromethyl, C₁-C₃ straight or branched chain alkyl, C₁-C₃ straight or branched chain alkenyl, C₁-C₃ alkoxy, C₁-C₃ alkenyloxy, phenoxy, benzyloxy, amino, thiocarbonyl, ester, thioester, cyano, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, and sulfonyl; wherein the individual ring sizes are 5-8 members; wherein the heterocyclic ring contains 1-4 heteroatom(s) selected from the group consisting of O, N, or S; wherein aromatic or tertiary alkyl amines are optionally oxidized to a corresponding N-oxide.

Particularly preferred Ar groups include phenyl, benzyl, naphthyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl,

pyrazolyl, and thienyl.

Preferred heterocyclic groups may be selected from the group consisting of pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, thienyl, piperidinyl, and piperazinyl.

A further particularly preferred embodiment of this invention is a compound of formula IV:



or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

15 n is 1, 2 or 3 forming a 5-7 member heterocyclic ring;

X is either O or S;

20 Y is a direct bond to Z, a C₁-C₃ straight or branched chain alkyl, or a C₂-C₃ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl,

sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₂, S, SO, or SO₂, wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

2 is a direct bond, or a C₁-C₄ straight or branched chain alkyl, or a C₁-C₄ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₂, S, SO, or SO₂, wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl

wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:

hydrogen, Ar, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, or $\text{C}_1\text{-C}_6$ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more position(s) with $\text{C}_1\text{-C}_6$ cycloalkyl, $\text{C}_3\text{-C}_6$ cycloalkenyl, hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups are optionally substituted with $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkenyl, hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR_1 , S, SO, or SO_2 , wherein R_1 is selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkyl, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkenyl or alkynyl, and $(\text{C}_1\text{-C}_6)$ bridging alkyl wherein said

bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

5 wherein Ar is an aryl or heteroaryl moiety which is substituted or unsubstituted;

W is oxygen or sulfur;

U is either O or N, wherein when U is O, then R_1 is a lone pair of electrons and R_2 is selected from the group consisting of:

10

Ar as defined above, $\text{C}_1\text{-C}_6$ cycloalkyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or alkenyl, or $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, halo, haloalkyl, hydroxy, trifluoromethyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SO, SO_2 , O, or NR_2 wherein R_2 is selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkyl, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkenyl or alkynyl, and $(\text{C}_1\text{-C}_6)$ bridging alkyl wherein said bridging alkyl forms a

15

20

25

heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or $\text{C}_1\text{-C}_6$ cycloalkyl;

5 and when U is N, R_1 and R_2 are selected independently from the group consisting of:

hydrogen, Ar as defined above, $\text{C}_1\text{-C}_6$ cycloalkyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or alkenyl, or $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, 10 halo, haloalkyl, hydroxy, trifluoromethyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, 15 alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SC, SC_2 , O, or NR_2 wherein R_2 is selected from the group consisting of hydrogen, 20 $(\text{C}_1\text{-C}_4)\text{-straight or branched chain alkyl}$, $(\text{C}_1\text{-C}_4)\text{-straight or branched chain alkenyl or alkynyl}$, and $(\text{C}_1\text{-C}_4)$ bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or 25 alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or $\text{C}_1\text{-C}_6$ cycloalkyl;

or R₁ and R₂ may be taken together to form a heterocyclic ring.

In preferred embodiments, Ar is a cyclic or fused cyclic ring and includes a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is
5 either unsubstituted or substituted in one to five position(s) with halo, haloalkyl, hydroxyl, nitro, trifluoromethyl, C₁-C₃ straight or branched chain alkyl, C₂-C₃ straight or branched chain alkenyl, C₁-C₃
10 alkoxy, C₁-C₃ alkenyloxy, phenoxy, benzyloxy, amino, thiocarbonyl, ester, thioester, cyano, imino, alkylamino, aminocalkyl, sulfhydryl, thioalkyl, and sulfonyl; wherein the individual ring sizes are 5-8 members; wherein the heterocyclic ring contains 1-4
15 heteroatom(s) selected from the group consisting of O, N, or S; wherein aromatic or tertiary alkyl amines are optionally oxidized to a corresponding N-oxide.

Particularly preferred Ar groups include phenyl, benzyl, naphthyl, pyrrolyl, pyrrolidinyl, pyridinyl,
20 pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, and thienyl.

Preferred heterocyclic groups may be selected from the group consisting of pyrrolyl, pyrrolidinyl,
25 pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl,

oxazolyl, thiazolyl, pyrazolyl, thienyl, piperidinyl, and piperazinyl.

Particularly preferred compounds of the present invention are selected from the group consisting of:

5 3-Phenylpropyl (2S)-1-(1-cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (17);

 Phenethyl (2S)-N-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (18);

10 3-(2,3,5-Trimethylphenyl)propyl 1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothioate (19);

 3-(2,3,5-Trimethylphenyl)propyl 1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (20);

 3-(3-Fluorophenyl)propyl (2S)-1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (21);

15 3-(2-Fluorophenyl)propyl (2S)-1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothioate (22);

 3-(2-Fluorophenyl)propyl (2S)-1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (23);

20 3-(4-Methylphenyl)propyl (2S)-1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (24);

 3-(4-Methylphenyl)propyl (2S)-1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothioate (25);

 3-(4-Methylphenyl)propyl (2S)-1-(tert-butylcarbamoyl)-2-pyrrolidinecarbothioate (26);

25 3-(2-Chlorophenyl)propyl (2S)-1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (27);

3-(3,5-Dimethoxyphenyl)propyl (2S)-1-([(1S)-1-(1-naphthyl)ethyl]-carbamoyl)-2-pyrrolidinecarbothioate (28);

3,3-Diphenylpropyl (2S)-1-[(1,1,3,3-tetramethylbutyl)carbamoyl]-2-pyrrolidinecarbothioate (29);

3-Cyclohexylpropyl (2S)-1-[(2,6-diisopropylphenyl)carbamoyl]-2-pyrrolidinecarbothioate (31);

3-Cyclohexylpropyl (2S)-1-(hexylcarbamoyl)-2-pyrrolidinecarbothioate (32);

3,3-Diphenylpropyl (2S)-1-[(2,4-dimethoxyphenyl)carbamoyl]-2-pyrrolidinecarbothioate (33);

3-(3,5-Dimethoxyphenyl)propyl (2S)-1-([(1S,2R)-2-phenyl-cyclopropyl]carbamoyl)-2-pyrrolidinecarbothioate (34);

3-Phenylpropyl (2S)-1-[(2,4-Dimethoxyphenyl)carbamoyl]-2-pyrrolidinecarbothioate (35);

3-Phenylpropyl (2S)-1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothioate (36);

3-Phenylpropyl (2S)-1-(1-cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (37);

3-Phenylpropyl (2S)-1-[1-adamantylamino)(thioxo)-methyl]-2-pyrrolidinecarbothioate (38);

- 3-(3,4,5-Trimethoxyphenyl)propyl (2S)-1-(hexylcarbamoyl)-2-pyrrolidinecarbothioate (39);
- 3-(3,4,5-Trimethoxyphenyl)propyl (2S)-1-(benzylcarbamoyl)-2-pyrrolidinecarbothioate (40);
- 5 3-Phenylpropyl (2S)-1-(dimethylcarbamoyl)-2-pyrrolidinecarbothioate (41);
- 3-Phenylpropyl (2S)-1-(1-pyrrolidinylcarbamoyl)-2-pyrrolidinecarbothioate (42);
- 3-Phenylpropyl (2S)-1-(morpholinocarbamoyl)-2-pyrrolidinecarbothioate (43);
- 10 3-Phenylpropyl (2S)-1-(diisopropylcarbamoyl)-2-pyrrolidinecarbothioate (44);
- 3-Phenylpropyl (2S)-1-[methyl(phenyl)carbamoyl]-2-pyrrolidinecarbothioate (45); and
- 15 3-Phenylpropyl (2S)-1-(diphenylcarbamoyl)-2-pyrrolidinecarbothioate.

The present invention also relates to a pharmaceutical composition comprising a neurotrophically effective amount of the compound of formula I, II, III or IV, and a pharmaceutically acceptable carrier.

20

The present invention further relates to a method of effecting a neuronal activity in an animal, comprising:

25

administering to the animal a neurotrophically

effective amount of the compound of formula I, II, III or IV.

The present invention further relates to the use of any of the compounds of Formula I, II, III, IV or in Table I below in the preparation of a medicament for the treatment of a disease such as peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

The present invention also contemplates processes for manufacturing the novel compounds, particularly the processes delineated below in Schemes 1 and 2.

15

DETAILED DESCRIPTION OF THE INVENTION

Definitions

"Alkyl" means a branched or unbranched saturated hydrocarbon chain comprising a designated number of carbon atoms. For example, C₁-C₆ straight or branched alkyl hydrocarbon chain contains 1 to 6 carbon atoms, and includes but is not limited to substituents such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, and the like, unless otherwise indicated.

25

"Alkenyl" means a branched or unbranched

unsaturated hydrocarbon chain comprising a designated number of carbon atoms. For example, C₂-C₆ straight or branched alkenyl hydrocarbon chain contains 2 to 6 carbon atoms having at least one double bond, and includes but is not limited to substituents such as ethenyl, propenyl, iso-propenyl, butenyl, iso-butenyl, tert-butenyl, n-pentenyl, n-hexenyl, and the like, unless otherwise indicated.

"Alkoxy" means the group -OR wherein R is alkyl as herein defined. Preferably, R is a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms.

"Ar" means an aryl or heteroaryl moiety which is substituted or unsubstituted, especially a cyclic or fused cyclic ring and includes a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to five position(s) with halo, haloalkyl, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, amino, thiocarbonyl, ester, thioester, cyano, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, and sulfonyl; wherein the individual ring sizes are 3-6 members; wherein the heterocyclic ring contains 1-4 heteroatom(s) selected from the group consisting of C,

N, or S; wherein aromatic or tertiary alkyl amines are optionally oxidized to a corresponding N-oxide. Particularly preferred aryl or heteroaryl moieties include but are not limited to phenyl, benzyl, naphthyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, and thienyl.

"Halo" means at least one fluoro, chloro, bromo, or iodo moiety, unless otherwise indicated.

"Phenyl" includes all possible isomeric phenyl radicals, optionally monosubstituted or multi-substituted with substituents selected from the group consisting of amino, halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₂-C₄ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, NR₁ wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₂-C₄)-straight or branched chain alkenyl or alkynyl, and (C₂-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is

optionally fused to an Ar group.

The term "pharmaceutically acceptable salt, ester, or solvate" refers to salts, esters, or solvates of the subject compounds which possess the
5 desired pharmacological activity and which are neither biologically nor otherwise undesirable. The salt, ester, or solvates can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate,
10 citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride hydrobromide, hydroiodide, 2-
15 hydroxyethanesulfonate, lactate, maleate, methanesulfonate, naphthylate, 2-naphthalenesulfonate, nicotinate, oxalate, sulfate, thiocyanate, tosylate and undecanoate. Base salt, ester, or solvates include ammonium salts, alkali metal salts such as
20 sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salt with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic
25 nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl,

ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

The compounds of this invention may possess at least one asymmetric center and thus can be produced as mixtures of stereoisomers or as individual enantiomers or diastereomers. The individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolution of the compound of formula (I). It is understood that the individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers are encompassed by the scope of the present invention. The S-stereoisomer at atom 1 of formula I is most preferred due to its greater activity.

"Isomers" are different compounds that have the same molecular formula and includes cyclic isomers such as (iso)indole and other isomeric forms of cyclic moieties.

"Stereoisomers" are isomers that differ only in

the way the atoms are arranged in space.

"Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other.

"Diastereoisomers" are stereoisomers which are
5 not mirror images of each other.

"Racemic mixture" means a mixture containing equal parts of individual enantiomers. "Non-racemic mixture" is a mixture containing unequal parts of individual enantiomers or stereoisomers.

10 The term "preventing neurodegeneration" as used herein includes the ability to prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease, or at risk of developing a new degenerative disease and for
15 preventing further neurodegeneration in patients who are already suffering from or have symptoms of a neurodegenerative disease.

The term "treatment" as used herein covers any treatment of a disease and/or condition in an animal,
20 particularly a human, and includes:

(i) preventing a disease and/or condition from occurring in a subject which may be predisposed to the disease and/or condition but has not yet been diagnosed as having it;

25 (ii) inhibiting the disease and/or condition, i.e., arresting its development; or

(iii) relieving the disease and/or condition, i.e., causing regression of the disease and/or condition.

The system used in naming the compounds of the present invention is shown below, using a compound of formula IV as an example.


A compound of the present invention, especially Formula IV, wherein n is 1, X is O, Y is (CH₂)₃, Z is CH, C is 3-pyridyl, D is H, W is O, U is N, R₁ is H and R₂ is 2-methylbutyl, is named 3-(3-pyridyl)-1-propylmercaptyl (2s)-1-[(2-methylbutyl) carbamoyl]pyrrolidine-2-carboxylate.

Compounds of the Invention

The neurotrophic low molecular weight, small molecule FKBP inhibitor compounds of this invention have an affinity for FKBP-type immunophilins, such as FKBP12. When the neurotrophic compounds of this invention are bound to an FKBP-type immunophilin, they have been found to inhibit the prolyl-peptidyl cis-trans isomerase activity, or rotamase, activity of the binding protein and unexpectedly stimulate neurite growth.

Specific exemplifications of these embodiments are presented in TABLE I.

TABLE I: COMPOUNDS



	No	n	W	Y	Z	C	D	R1	R2
	1	1	O	(CH ₂) ₂	CH	3-Pyridyl	H	H	2-Methylbutyl
	2	1	O	(CH ₂) ₂	CH	3-Pyridyl	H	H	1,1-dimethylpropyl
10	3	1	O	(CH ₂) ₂	CH	4-Methoxy phenyl	H	H	1,1-dimethylpropyl
	4	1	O	CH ₂	CH	Phenyl	H	H	1,1-dimethylpropyl
	5	1	S	(CH ₂) ₂	CH	4-Methoxy phenyl	H	H	Cyclohexyl
	6	1	O	(CH ₂) ₂	CH	3-Pyridyl	H	H	Cyclohexyl
	7	1	S	(CH ₂) ₂	CH	3-Pyridyl	H	H	Cyclohexyl
15	8	1	S	(CH ₂) ₂	CH	3-Pyridyl	H	H	1-Adamantyl
	9	1	S	(CH ₂) ₂	CH	3-Pyridyl	H	H	1,1-dimethylpropyl
	10	1	O	(CH ₂) ₂	CH	Phenyl	Phenyl	H	1,1-dimethylpropyl
	11	2	O	(CH ₂) ₂	CH	Phenyl	H	H	1,1-dimethylpropyl
	12	2	O	(CH ₂) ₂	CH	Phenyl	H	H	Phenyl
20	13	2	O	Direct Bond	CH	2-Phenyl ethyl	2-Phenyl ethyl	H	Phenyl
	14	2	O	Direct Bond	CH	2-Phenyl ethyl	2-Phenyl ethyl	H	Cyclohexyl
	15	2	S	Direct Bond	CH	2-Phenyl ethyl	2-Phenyl ethyl	H	Cyclohexyl
	16	2	O	(CH ₂) ₂	CH	4-Methoxy phenyl	H	H	Cyclohexyl
	17	1	O	(CH ₂) ₂	CH	Phenyl	H	H	Cyclohexyl

	No	n	W	Y	Z	C	D	R1	R2
	18	1	O	CH ₂	CH	Phenyl	H	H	Cyclohexyl
	19	1	O	(CH ₂) ₂	CH	2,3,5 Tri methylphenyl	H	H	Adamantyl
	20	1	O	(CH ₂) ₂	CH	2,3,5 Tri methylphenyl	H	H	Cyclohexyl
	21	1	O	(CH ₂) ₂	CH	3-Fluoro phenyl	H	H	Cyclohexyl
5	22	1	O	(CH ₂) ₂	CH	2-Fluoro phenyl	H	H	Adamantyl
	23	1	O	(CH ₂) ₂	CH	2-Fluoro phenyl	H	H	Cyclohexyl
	24	1	O	(CH ₂) ₂	CH	4-Methyl phenyl	H	H	Cyclohexyl
	25	1	O	(CH ₂) ₂	CH	4-Methyl phenyl	H	H	Adamantyl
	26	1	O	(CH ₂) ₂	CH	4-Methyl phenyl	H	H	Tert-butyl
10	27	1	O	(CH ₂) ₂	CH	2-Chloro phenyl	H	H	Cyclohexyl
	28	1	O	(CH ₂) ₂	CH	3,5-Dimeth oxyphenyl	H	H	1-Napthylethyl
	29	1	O	(CH ₂) ₂	CH	Phenyl	Phenyl	H	1,1,3,3- Tetramethylbutyl
	31	1	O	(CH ₂) ₂	CH	Cyclohexyl	H	H	2,6-Diisopropyl phenyl
	32	1	O	(CH ₂) ₂	CH	Cyclohexyl	H	H	Hexyl
15	33	1	O	(CH ₂) ₂	CH	Phenyl	Phenyl	H	2,4-Dimethoxy phenyl
	34	1	O	(CH ₂) ₂	CH	3,5-Dimeth oxyphenyl	H	H	2-Phenylcyclo propyl
	35	1	O	(CH ₂) ₂	CH	Phenyl	H	H	2,4-Dimethoxy phenyl
	36	1	O	(CH ₂) ₂	CH	Phenyl	H	H	Adamantyl
	37	1	O	(CH ₂) ₂	CH	Phenyl	H	H	Cyclohexyl
20	38	1	O	(CH ₂) ₂	CH	Phenyl	H	H	Adamantyl
	39	1	O	(CH ₂) ₂	CH	(3,4,5- Trimethoxy) phenyl	H	H	Hexyl
	40	1	O	(CH ₂) ₂	CH	(3,4,5- Trimethoxy) phenyl	H	H	Benzyl

	No	n	W	Y	Z	C	D	R1	R2
	41	1	O	(CH ₂) ₂	CH	Phenyl	H	CH ₃	CH ₃
	42	1	O	(CH ₂) ₂	CH	Phenyl	H	R ₁ , R ₂ = -CH ₂ -CH ₂ -CH ₂ -CH ₂ - (cyclic)	
	43	1	O	(CH ₂) ₂	CH	Phenyl	H	R ₁ , R ₂ = -CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - (cyclic)	
	44	1	O	(CH ₂) ₂	CH	Phenyl	H	R ₁ =R ₂ =Diisopropyl	
5	45	1	O	(CH ₂) ₂	CH	Phenyl	H	CH ₃ Phenyl	
	46	1	O	(CH ₂) ₂	CH	Phenyl	H	R ₁ =R ₂ =Phenyl	

The compounds of the present invention exist as stereoisomeric forms, either enantiomers or diastereoisomers. Included within the scope of the invention are the enantiomers, the racemic form, and diastereoisomeric mixtures. Enantiomers and diastereoisomers can be separated by methods known to those skilled in the art.

Methods of Using the Compounds of the Invention

The compounds of the present invention have an affinity for the FK506 binding protein, particularly FKBP12, which is present in the neuronal tissue. When the inventive compounds bind to FKBP in neuronal tissue, they exhibit excellent neurotrophic activity. This activity is useful in the stimulation of damaged neurons, the promotion of neuronal regeneration, the prevention of neurodegeneration, and the treatment of several neurological disorders known to be associated with neuronal degeneration and peripheral neuropathies.

For the foregoing reasons, the present invention further relates to a method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of a compound of formula I, II, III or IV.

In a preferred embodiment, the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

The compounds of the present invention are particularly useful for preventing neurodegeneration in patients suffering from a neurodegenerative disease or who have symptoms of a neurodegenerative disease. The compounds are also useful for preventing neurodegeneration in patients newly diagnosed as having a neurodegenerative disease or at risk for developing a neurodegenerative disease. These compounds are also useful for, but not limited to, preventing neurodegeneration in patients suffering from Parkinson's disease or having symptoms of Parkinson's disease. These treatment methods are exemplified in the MPTP Model and data described herein.

The neurological disorders that may be treated include but are not limited to: trigeminal neuralgia; glossopharyngeal neuralgia; Bell's Palsy; myasthenia gravis; muscular dystrophy; amyotrophic lateral sclerosis; progressive muscular atrophy; progressive bulbar inherited muscular atrophy;

herniated; ruptured or prolapsed invertebrate disk.
syndromes; cervical spondylosis; plexus disorders;
thoracic outlet destruction syndromes; peripheral
neuropathic such as those caused by lead, dapsone,
5 ticks, porphyria, or Guillain-Barre syndrome;
Alzheimer's disease; and Parkinson's disease.

The compounds of the present invention are particularly useful for treating a neurological disorder selected from the group consisting of:
10 peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration. Examples of
15 neurological disorders relating to neurodegeneration are Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

Pharmaceutical Compositions of the Invention

The present invention also relates to a pharmaceutical composition comprising:
20

- (i) a neurotrophically effective amount of the compound of formula I, II, III or IV, and
- (ii) a pharmaceutically acceptable carrier.

The above discussion relating to the utility
25 and administration of the compounds of the present invention also applies to the pharmaceutical

compositions of the present invention.

The term "pharmaceutically acceptable carrier" as used herein refers to any carrier, diluent, excipient, suspending agent, lubricating agent, adjuvant, vehicle, delivery system, emulsifier, disintegrant, absorbant, preservative, surfactant, colorant, flavorant, or sweetener.

For these purposes the compounds of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally, intraventricularly, intrasternal and intracranial injection or infusion techniques.

For oral administration, the compounds of the present invention may be provided in any suitable dosage form known in the art. For example, the compositions may be incorporated into tablets, powders, granules, beads, chewable lozenges, capsules, liquids, aqueous suspensions or solutions, or similar dosage forms, using conventional equipment and techniques known in the art. Tablet

dosage forms are preferred. Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate.

5 Capsules may contain diluents including lactose and dried corn starch. Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient.

When preparing dosage form incorporating the compositions of the invention, the compounds may
10 also be blended with conventional excipients such as binders, including gelatin, pregelatinized starch, and the like; lubricants, such as hydrogenated vegetable oil, stearic acid, and the like; diluents, such as lactose, mannose, and sucrose;
15 disintegrants, such as carboxymethylcellulose and sodium starch glycolate; suspending agents, such as povidone, polyvinyl alcohol, and the like; absorbants, such as silicon dioxide; preservatives, such as methylparaben, propylparaben, and sodium
20 benzoate; surfactants, such as sodium lauryl sulfate, polysorbate 80, and the like; colorants such as F.D. & C. dyes and lakes; flavorants; and sweeteners.

Compositions and methods of the invention also
25 may utilize controlled release technology. Thus, for example, the inventive compounds may be

incorporated into a hydrophobic polymer matrix for controlled release over a period of days. Such controlled release films are well known to the art. Particularly preferred are transdermal delivery systems. Other examples of polymers commonly employed for this purpose that may be used in the present invention include nondegradable ethylene-vinyl acetate copolymer and degradable lactic acid-glycolic acid copolymers which may be used externally or internally. Certain hydrogels such as poly(hydroxyethylmethacrylate) or poly(vinylalcohol) also may be useful, but for shorter release cycles than the other polymer releases systems, such as those mentioned above.

To be effective therapeutically as central nervous system targets, the compounds of the present invention should readily penetrate the blood-brain barrier when peripherally administered. Compounds which cannot penetrate the blood-brain barrier can be effectively administered by an intraventricular route or other appropriate delivery system suitable for administration to the brain.

The compounds of the present invention may be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These

suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be
5 sterile injectable solutions or suspensions in non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic
10 sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvents or suspending mediums. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids such as oleic acid
15 and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated versions, are useful in the preparation of injectables. These oil solutions or suspensions may also contain long-chain alcohol diluents or
20 dispersants.

The compounds of this invention may also be administered rectally in the form of suppositories. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which
25 is solid at room temperature, but liquid at rectal temperature and, therefore, will melt in the rectum

to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The compounds of this invention may also be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas.

For topical application to the eye, or ophthalmic use, the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively for the ophthalmic uses the compounds may be formulated in an ointment such as petrolatum.

For topical application to the skin, the compounds can be formulated in a suitable ointment containing the compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and

water. Alternatively, the compounds can be formulated in a suitable lotion or cream containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following:
5 mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

Topical application for the lower intestinal tract can be effected in a rectal suppository
10 formulation (see above) or in a suitable enema formulation.

Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions,
15 with preferred levels of about 0.1 mg to about 1,000 mg. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

20 It is understood, however, that a specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration,
25 rate of excretion, drug combination, and the severity of the particular disease being treated and

form of administration.

The compounds can be administered with other neurotrophic agents such as neurotrophic growth factor (NGF), glial derived growth factor, brain
5 derived growth factor, ciliary neurotrophic factor, and neurotrophin-3. The dosage level of other neurotrophic drugs will depend upon the factors previously stated and the neurotrophic effectiveness of the drug combination.

10


The present invention relates to the use of any of the compounds seen in Table I in the preparation of a medicament for the treatment of a disease such as peripheral neuropathy caused by physical injury
15 or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

20

The present invention also contemplates processes for manufacturing the novel compounds, particularly the processes delineated in schemes 1 and 2.

Methods of Making the Compounds of the Invention:

The novel compounds of this invention may be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathway depicted below. As described by Scheme 1, cyclic amino acids 1 protected by suitable blocking groups P on the amino acid nitrogen may be reacted with thiols RSH to generate thioesters 2. After removal of the protecting group, the free amine 3 may be reacted with a variety of isocyanates or isothiocyanates to provide the final ureas or thioureas, respectively.




SCHEME 1

Isocyanates ($R'NCO$) or isothiocyanates ($R'NCS$).


4 may be conveniently prepared from the corresponding readily available amines by reaction with phosgene or thiophosgene, as depicted in Scheme

5 2.



SCHEME 2

Thiols $R-SH$ may be conveniently prepared from the corresponding readily available alcohols or halides via a two step replacement of halide by sulfur, as described in Scheme 3. Halides may be reacted with thiourea, and the corresponding alkyl thiouronium salts hydrolyzed to provide thiols RSH . If alcohols are used as the starting materials, they may be first converted to the corresponding halides by standard methods.



SCHEME 3

Examples

The following examples are illustrative of the present invention and are not intended to be limitations thereon. Unless otherwise specified, all percentages are based on 100% by weight of the final compound.

EXAMPLE 1

10 Synthesis of 3-(3-Pyridyl)-1-propylmercaptan 2S-1-[(2-methylbutyl)carbamoyl]pyrrolidine-2-carboxylate
(1)

3-(3-Pyridyl)-1-propylchloride

15 To a solution of 3-(3-pyridyl)-1-propanol (10 g; 72.4 mmol) in chloroform (100 mL) was added dropwise a solution of thionyl chloride (12.9 g;

108.6 mmol) in chloroform (50 mL). The resulting mixture was refluxed for 1 hour, then poured into ice-cold 50% aqueous potassium hydroxide (150 mL). The layers were separated, and the organic phase was dried, concentrated, and purified on a silica gel column, eluting with 40% ethylacetate in hexane, to obtain 10 g (65%) of the chloride as a clear oil, ¹H NMR (300 MHz, CDCl₃): δ 2.02-2.11 (m, 2H); 2.77 (m, 2H); 3.51 (m, 2H); 7.20 (m, 1H); 7.49 (m, 1H); 8.45 (m, 2H).

3-(3-Pyridyl)-1-propylmercaptan

A mixture of 3-(3-pyridyl)-1-propylchloride (3 g; 19.4 mmol) and thiourea (1.48 g; 19.4 mmol) in ethanol (10 mL) was refluxed for 24 hours. Aqueous sodium hydroxide, 15 mL of a 0.75 N solution, was added, and the mixture was refluxed for an additional 2 hrs. After cooling to room temperature, the solvent was removed in vacuo. Chromatographic purification of the crude thiol on a silica gel column eluting with 50% ethyl acetate in hexane delivered 1.2 g of 3-(3-Pyridyl)-1-propylmercaptan as a clear liquid ¹H NMR (300 MHz, CDCl₃): δ 1.34 (m, 1H); 1.90 (m, 2H); 2.52 (m, 2H); 2.71 (m, 2H); 7.81 (m, 1H); 7.47 (m, 1H); 8.42 (m, 2H).

3-(3-Pyridyl)-1-propylmercaptanyl N-(tert-butylloxycarbonyl)pyrrolidine-2-carboxylate

A mixture of N-(tert-butylloxycarbonyl)-(S)-proline (3.0 g; 13.9 mmol); 3-(3-Pyridyl)-1-propylmercaptan (3.20 g; 20.9 mmol),
dicyclohexylcarbodiimide (4.59 g; 22.24 mmol), camphorsulfonic acid (1.08 g; 4.63 mmol), and 4-dimethylaminopyridine (0.60 g; 4.63 mmol) in dry methylene chloride (100 mL) was stirred overnight.
The reaction mixture was diluted with methylene chloride (50 mL) and water (100 mL), and the layers were separated. The organic phase was washed with water (3 x 100 mL), dried over magnesium sulfate, and concentrated, and the crude residue was purified on a silica gel column eluting with ethyl acetate to obtain 4.60 g (95%) of the thioester as a thick oil.
¹H NMR (300 MHz, CDCl₃): δ 1.45 (s, 9H); 1.70-2.05 (m, 5H); 2.32 (m, 1H); 2.71 (t, 2H); 2.85 (m, 2H); 3.50 (m, 2H); 4.18 (m, 1H); 7.24 (m, 1H); 7.51 (m, 1H); 8.48 (m, 2H).

3-(3-Pyridyl)-1-propylmercaptanyl pyrrolidine-2-carboxylate

A solution of 3-(3-Pyridyl)-1-mercaptanyl N-(tert-butylloxycarbonyl)pyrrolidine-2-carboxylate (4.60 g; 13.1 mmol) in methylene chloride (60 mL)

and trifluoroacetic acid (6 mL) was stirred at room temperature for three hours. Saturated potassium carbonate was added until the pH was basic, and the reaction mixture was extracted with methylene chloride (3x). The combined organic extracts were dried and concentrated to yield 2.36 g (75%) of the free amine as a thick oil, ¹H NMR (300 MHz, CDCl₃): δ 1.87-2.20 (m, 6H); 2.79 (m, 2H); 3.03-3.15 (m, 4H total); 3.34 (m, 1H); 7.32 (m, 1H); 7.60 (m, 1H); 8.57 (m, 2H).

3-(3-Pyridyl)-1-propylmercaptyl 2S-1-1 2-methylbutyl carbamoylpyrrolidine-2-carboxylate (1)

A solution of 2-methylbutylamine (113 mg; 1.3 mmol) and triethylamine (132 mg; 1.3 mmol) in methylene chloride (5 mL) was added to a solution of triphosgene (128 mg; 0.43 mmol) in methylene chloride (5 mL). The resulting mixture was refluxed for 1 hour and then cooled to room temperature. 3-(3-Pyridyl)-1-propylmercaptyl pyrrolidine-2-carboxylate (300 mg; 1.3 mmol) in 5 mL of methylene chloride was added and the resulting mixture was stirred for 1 hour and then partitioned between water and a 1:1 mixture of ethyl acetate and hexane. The organic phase was dried, concentrated and purified by column chromatography (50% ethyl

acetate/hexane) to obtain 250 mg (55%) of the compound of Example 1 (1, Table 1) as an oil, ¹H NMR (300 MHz, CDCl₃): δ 0.89-0.93 (m, 6H); 1.10-1.20 (m, 1H); 1.27 (s, 1H); 1.36-1.60 (m, 2H); 1.72 (s, 2H); 1.97-2.28 (m, 6H); 2.70-2.75 (m, 2H); 2.92-3.54 (m, 6H); 4.45-4.47 (m, 1H); 7.21-7.29 (m, 1H); 7.53-7.56 (dd, 1H); 8.46-8.48 (s, 2H).

10

Example 2

Synthesis of 3-(3-Pyridyl)-1-propyl 2S-1-((1',1'-Dimethylpropyl)carbamoyl)pyrrolidine-2-carboxylate
(2)

Reaction of 3-(3-pyridyl)-1-propylmercaptyl pyrrolidine-2-carboxylate with the isocyanate generated from tert-amylamine and triphosgene, as described for Example 1, provided the compound of Example 2 (2, Table 1) in 62% yield, ¹H NMR (CDCl₃, 300 MHz): δ 0.83 (t, 3H); 1.27 (s, 6H); 1.64-1.71 (m, 2H); 1.91-2.02 (m, 7H); 2.66-2.71 (t, 2H); 2.85 (m, 2H); 3.29-3.42 (m, 2H); 4.11 (br, 1H); 4.37-4.41 (m, 1H).

25

Example 3

Synthesis of 3-(3-pyridyl)-1-propylmercaptyl 2S-1-
1-(cyclohexyl)thiocarbamoyl-pyrrolidine-2-
5 carboxylate

(7)

A mixture of cyclohexylisothiocyanate (120 mg; 0.9 mmol), 3-(3-pyridyl)-1-propylmercaptyl pyrrolidine-2-carboxylate (200 mg; 0.9 mmol) and triethylamine
10 (90 mg; 0.9 mmol) in 20 mL of methylene chloride was the resulting mixture was stirred for 1 hour and then partitioned between water and a 1:1 mixture of ethyl acetate and hexane. The organic phase was dried, concentrated and purified by column
15 chromatography (50% ethyl acetate/hexane) to obtain 160 mg (47%) of the compound of Example 3 (7, Table I), ¹H NMR (CDCl₃, 300 MHz): δ 1.16-1.40 (m, 6H); 1.50-1.71 (m, 4H); 1.95-2.08 (m, 7H); 2.70-2.75 (t, 2H); 3.03 (m, 2H); 3.40-3.60 (m, 2H); 4.95-4.98 (d, 20 1H); 5.26-5.29 (d, 1H); 7.17-7.23 (m, 1H).

EXAMPLE 4

Synthesis of 3-Phenylpropyl (2S)-1-(1-
25 cyclohexylcarbamoyl)-
2-pyrrolidinecarbothioate(17)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a stick white solid, with a chemical formula of $C_{21}H_{29}N_2O_2S$, a molecular weight of 375.56, 1H NMR ($CDCl_3$, 300 MHz): δ 1.10-1.19 (m, 4H); 1.30-1.38 (m, 3H); 1.61-1.71 (m, 2H); 1.84-2.03 (m, 6H); 2.65 (t, 2H, $J=7.75$); 2.87 (t, 2H, $J=7.57$); 3.33-3.39 (m, 1H); 3.46-3.50 (m, 1H); 3.63-3.67 (m, 1H); 4.18 (d, 2H, $J=7.85$); 4.55 (dd, 1H, $J=2.14, 6.05$); 7.11-7.29 (m, 5H). Thin Layer Chromatography yielded a result of $R_f = 0.43$ (50% ETOAc/Hexane).

EXAMPLE 3

15 Synthesis of Phenethyl (2S)-N-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (13)

The compound was prepared in accordance with the procedures used for the above examples and yielded an optically pure compound as a clear oil with a molecular formula of $C_{21}H_{29}N_2O_2S$, molecular weight of 360.63, 1H NMR ($CDCl_3$, 300 MHz): δ 1.06-1.38 (m, 7H); 1.61-1.72 (m, 2H); 1.93-2.13 (m, 4H); 2.84 (t, 2H, $J=7.57$); 3.10 (t, 2H, $J=7.0$); 3.33-3.35 (m, 1H); 3.44-3.45 (m, 1H); 3.64-3.67 (m, 1H); 4.17 (bd, 1H, $J=7.94$); 4.55 (bd, 1H, $J=3.37$); 7.20-7.31 (m, 5H). Thin Layer Chromatography yielded a result

of $R_f = 0.18$ (50% Hexane:EtOAc).

EXAMPLE 6

Synthesis of 3-(2,3,5-Trimethylphenyl)propyl 1-(1-
 5 adamantylcarbamoyl)-2-pyrrolidinecarbothioate (19)

The compound was prepared in accordance with the above examples and yielded an optically pure compound as a colorless oil with a molecular formula of $C_{29}H_{43}N_2O_2S$, molecular weight of 468.66, 1H NMR
 10 (CDCl₃, 300 MHz): δ 1.50 (s, 3H); 1.67 (bs, 5H); 1.82-1.90 (m, 2H); 2.01 (s, 6H); 2.15-2.20 (m, 4H); 2.10 (s, 3H); 2.15 (s, 3H); 2.19 (s, 3H); 2.63 (t, 2H, $J=6.66$); 3.30 (m, 1H); 3.42 (m, 1H); 4.15 (s, 1H); 4.52 (m, 1H); 7.01 (d, 2H, $J=10.48$). Thin
 15 Layer Chromatography yielded a result of $R_f = 0.82$ (80% EtOAc/hexane).

EXAMPLE 7

Synthesis of 3-(2,3,5-Trimethylphenyl)propyl 1-
 20 (cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (20)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a colorless oil with a molecular formula of $C_{24}H_{36}N_2O_2S \cdot 0.75 H_2O$, a
 25 molecular weight of 430.13, 1H NMR (CDCl₃, 300 MHz): δ 1.06-1.19 (m, 3H); 1.22-1.43 (m, 2H); 1.53-1.55

(m, 1H); 1.71-1.74 (m, 2H); 1.75-1.80 (m, 2H); 1.81-1.85 (m, 3H); 1.96-2.03 (m, 2H); 2.10 (s, 3H); 2.15 (s, 3H) 2.20 (s, 3H); 2.63 (t, 2H, J=7.96); 2.90 (t, 2H); 3.38 (q, 1H); 3.40-3.43 (m, 1H); 3.61-3.69 (m, 1H); 4.19 (d, 1H, J=8.22); 4.56 (d, 1H); 6.95 (d, 2H, J=12.05). Thin Layer Chromatography yielded a result of $R_f = 0.47$ (80% EtOAc/hexane).

EXAMPLE 8

10 Synthesis of 3-(3-Fluorophenyl)propyl (2S)-1-(Cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (21)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a white solid with a molecular formula of $C_{22}H_{32}N_2O_2S$, a molecular weight of 392.56, 1H NMR ($CDCl_3$, 300 MHz): δ 1.07-1.43 (m, 6H); 1.63-1.73 (m, 2H); 1.67-2.09 (cm, 7H); 2.67 (t, 2H, J=7.46); 2.85 (t, 2H, J=7.46); 3.35-3.37 (m, 1H); 3.46-3.48 (m, 1H); 3.65-3.67 (m, 1H); 4.19 (d, 1H, J=7.84); 4.55 (d, 1H, J=7.90); 6.84-6.95 (m, 3H); 7.21-7.24 (m, 1H). Thin Layer Chromatography yielded a result of $R_f = 0.19$ (20% EtOAc/hexane).

EXAMPLE 9

25 Synthesis of 3-(2-Fluorophenyl)propyl (2S)-1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothioate (22)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a colorless oil with a molecular formula of $C_{23}H_{33}N_2O_2SF_6$, a molecular weight of 444.64, 1H NMR ($CDCl_3$, 300 MHz): δ 1.66 (bs, 5H); 1.99 (s, 2H); 2.04 (bs, 6H); 2.06-2.19 (bs, 6H); 2.25 (m, 1H); 2.69 (t, 2H); 2.86 (t, 2H); 3.42 (m, 1H); 3.57 (m, 1H); 4.25 (m, 2H); 4.67 (m, 1H); 7.05 (m, 2H); 7.18 (m, 2H). Thin Layer Chromatography yielded a result of $R_f = 0.70$ (EtOAc).

EXAMPLE 10

Synthesis of 3-(2-Fluorophenyl)propyl (2S)-1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (23)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a white solid with a molecular formula of $C_{21}H_{33}N_2O_2SF_6$, a molecular weight of 392.56, 1H NMR ($CDCl_3$, 300 MHz): δ 1.23-1.32 (m, 3H); 1.41-1.49 (m, 3H); 1.74-1.82 (m, 2H); 1.93-2.09 (cm, 6H); 2.15-2.23 (m, 1H); 2.73 (t, 2H); 2.94 (t, 2H); 3.42-3.51 (m, 1H); 3.54-3.61 (m, 1H); 3.61-3.74 (m, 1H); 4.24 (d, 1H); 4.56 (d, 1H); 6.91-7.03 (m, 2H); 7.15-7.24 (m, 2H). Thin Layer Chromatography yielded a result of $R_f = 0.65$.

EXAMPLE 11Synthesis of 3-(4-Methylphenyl)propyl (2S)-1-(cyclohexylcarbamoyl)-2-pyrrolidinecarbothionate (24)

The Compound was prepared in accordance with
the procedures used in the above examples and
yielded an optically pure compound as a white solid
with a molecular formula of $C_{22}H_{32}N_2O_5S \cdot 0.25$ EtOAc, a
molecular weight of 410.60, 1H NMR ($CDCl_3$, 300 MHz):
 δ 1.01-1.21 (m, 3H); 1.30-1.44 (m, 2H); 1.61-1.69
(m, 2H); 1.75-2.13 (cm, 8H); 2.30 (s, 3H); 2.63 (t, 2H);
2.84 (t, 2H); 3.61 (q, 1H); 3.65-3.69 (m, 1H); 3.72-
3.76 (m, 1H); 4.21 (d, 1H); 4.59 (d, 1H); 7.05-7.25
(m, 4H). Thin Layer Chromatography yielded a result
of $R_f = 0.84$ (30% EtOAc/hexane).

15

EXAMPLE 12Synthesis of 3-(4-Methylphenyl)propyl (2S)-1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothionate (25)

The compound was prepared in accordance with
the procedures used in the above examples and
yielded an optically pure compound as a colorless
oil with a molecular formula of $C_{25}H_{34}N_2O_5S \cdot 0.10$
EtOAc, a molecular weight of 450.46, 1H NMR ($CDCl_3$,
300 MHz): δ 1.54 (s, 5H); 1.66 (bs, 6H); 1.85 (q, 1H);
2.03 (s, 8H); 2.09 (s, 4H); 2.63 (t, 2H); 2.86 (t, 2H);
3.33 (q, 1H); 3.35 (m, 1H); 4.08 (s, 1H); 4.52 (d, 1H);

25

7.03-7.14 (m, 4H). Thin Layer Chromatography yielded a result of $R_f = 0.68$ (80% EtOAc/hexane).

EXAMPLE 13

5 Synthesis of 3-(4-Methylphenylpropyl (2S)-1-(tert-butylcarbamoyl)-2-pyrrolidinecarboxylate (26)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a colorless
10 oil with a molecular formula of $C_{26}H_{30}N_2O_5 \cdot 0.3 H_2O$, a molecular weight of 367.94, 1H NMR ($CDCl_3$, 300 MHz):
 δ 1.43 (s, 9H); 1.82-1.91 (m, 2H); 1.95-2.13 (m, 4H);
2.31 (s, 3H); 2.76 (t, 2H); 2.89 (t, 2H); 3.41-3.43
(m, 1H); 3.46-3.49 (m, 1H); 4.24 (bs, 1H); 4.61 (d, 1H);
15 7.09-7.12 (m, 4H). Thin Layer Chromatography yielded a result of $R_f = 0.50$ (50% EtOAc/hexane).

EXAMPLE 14

20 Synthesis of 3-(2-Chlorophenylpropyl (2S)-1-cyclohexylcarbamoyl)-2-pyrrolidinecarboxylate (27)

The Compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a light foam
with a molecular formula of $C_{21}H_{27}N_2O_5 \cdot Cl$, a molecular
25 weight of 408.99, 1H NMR ($CDCl_3$, 400 MHz): δ 1.05-
1.42 (m, 7H); 1.61-1.78 (m, 3H); 1.83-2.17 (m, 5H);

2.87 (t, 2H); 3.05 (q, 2H); 3.42 (q, 1H); 3.57 (m, 1H);
 3.61-3.67 (m, 1H); 4.21 (d, 1H); 4.64 (d, 1H); 7.20-
 7.31 (m, 3H); 7.56-7.59 (m, 1H). Thin Layer
 Chromatography yielded a result of $R_f = 0.78$
 5 (EtOAc).

EXAMPLE 15

Synthesis of 3-(3,5-Dimethoxyphenyl)propyl (2S)-1-[(1S)-1-(1-naphthyl)ethyl-carbamoyl]-2-
pyrrolidinecarbothioate (28)
 10

The compound was prepared in accordance with
 the procedures used in the above examples and
 yielded an optically pure compound as a colorless
 oil with a molecular formula of $C_{33}H_{31}N_2O_5S \cdot 0.75 H_2O \cdot$
 15 $0.60 EtOAc$, a molecular weight of 573.04, 1H NMR
 ($CDCl_3$, 400 MHz): δ 1.65 (d, 3H, $J=6.76$); 1.83-1.96
 (m, 2H); 1.99-2.07 (m, 3H); 2.60 (t, 2H, $J=7.51$); 2.85
 (t, 2H, $J=7.27$); 3.29-3.68 (m, 2H); 3.73 (s, 6H); 4.56
 (d, 1H, $J=6.10$); 4.76 (d, 1H, $J=7.51$); 5.78-5.79 (m, 1H);
 20 6.29-6.32 (m, 3H); 7.40-7.76 (m, 4H); 7.81
 (d, 1H, $J=6.90$); 7.83 (d, 1H, $J=7.35$); 8.17
 (d, 1H, $J=7.72$). Thin Layer Chromatography yielded a
 result of $R_f = 0.09$ (50% EtOAc/hexane).

25

EXAMPLE 16

Synthesis of 3,3'-Diphenylpropyl (2S)-1-[(1,1,3,3-

tetramethylbutyl)carbamoyl-2-
pyrrolidinecarbothioate (29)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a colorless oil with a molecular formula of $C_{23}H_{40}N_2O_2S \cdot 0.25$ EtOAc, molecular weight of 392.74, 1H NMR ($CDCl_3$, 400 MHz): δ 0.88 (t, 2H, $J=6.57$); 1.02 (s, 9H); 1.41 (s, 3H); 1.42 (s, 3H); 1.81 (d, 1H, $J=14.90$); 1.65 (d, 1H, $J=14.90$); 2.04-2.07 (m, 1H); 2.29 (q, 2H, $J=7.83$); 2.77 (t, 2H, $J=6.97$); 3.29-3.30 (m, 1H); 3.40-3.42 (m, 1H); 4.00 (t, 1H, $J=7.83$); 4.32 (s, 1H); 4.53 (dd, 1H, $J=1.96, 7.92$); 7.10-7.27 (m, 10H). Thin Layer Chromatography yielded a result of $R_f = 0.43$ (50% EtOAc/hexane).

EXAMPLE 17

Synthesis of 3-Cyclohexylpropyl (2S)-1-[(2,6-
diisopropylphenyl)carbamoyl-2-
pyrrolidinecarbothioate (31)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a white solid with a molecular formula of $C_{31}H_{44}N_2O_2S$, a molecular weight of 458.68, 1H NMR ($CDCl_3$, 400 MHz): δ 0.76-0.91 (m, 2H); 1.15-1.43 (m, 18H); 1.59-1.61 (m, 2H);

1.63-1.82 (m, 5H); 2.09-2.36 (m, 4H); 2.83 (t, 2H);
 3.24 (t, 2H); 3.51-3.79 (m, 2H); 4.67-4.71 (m, 1H)
 7.15-7.20 (m, 2H); 7.26-7.31 (m, 1H). Thin Layer
 Chromatography yielded a result of $R_f = 0.72$ (50%
 5 EtOAc/hexane).

EXAMPLE 18

Synthesis of 3-Cyclohexylpropyl (2S)-1-(hexylcarbamoyl)-2-pyrrolidinecarbothioate (32)

10 The compound was prepared in accordance with
 the procedures used in the above examples and
 yielded an optically pure compound as a colorless
 oil with a molecular formula of $C_{21}H_{32}N_2O_2S \cdot 0.05 H_2O$, a
 molecular weight of 483.51, 1H NMR (CDCl₃, 400 MHz):
 15 δ 0.76-0.91 (m, 2H); 1.15-1.43 (m, 18H); 1.59-1.61
 (m, 2H); 1.63-1.82 (m, 5H); 2.09-2.36 (m, 4H); 2.83
 (t, 2H); 3.24 (t, 2H); 3.51-3.79 (m, 2H); 4.67-4.71
 (m, 1H); 7.15-7.20 (m, 2H); 7.26-7.31 (m, 1H). Thin
 Layer Chromatography yielded a result of $R_f = 0.35$
 20 (50% EtOAc/hexane).

EXAMPLE 19

Synthesis of 3,3-Diphenylpropyl (2S)-1-[(2,4-dimethoxyphenyl)carbamoyl]-2-pyrrolidinecarbothioate (33)

25 (33)

The compound was prepared in accordance with

the procedures used in the above examples and yielded an optically pure compound as a white solid with a molecular formula of $C_{23}H_{32}N_2O_4S$, molecular weight of 504.33, 1H NMR ($CDCl_3$, 400 MHz): δ 2.05-2.19 (m, 4H); 2.30 (q, 2H, $J=8.06$); 2.73 (td, 2H, $J=2.89, 7.10$); 3.58 (q, 1H, $J=7.57$); 3.66-3.76 (m, 1H); 3.77 (t, 3H); 3.80 (s, 3H); 3.99 (t, 1H, $J=7.76$); 4.65 (dd, 1H, $J=2.08, 8.12$); 6.43-6.45 (m, 2H); 7.14-7.28 (m, 10H); 8.05 (d, 1H, $J=9.80$). Thin Layer Chromatography yielded a result of $R_f = 0.63$ (EtOAc).

EXAMPLE 20

15 Synthesis of 3-(3,5-Dimethoxyphenyl)propyl (2S)-1-((1S,2R)-2-phenyl-cyclopropyl)carbamoyl-2-pyrrolidinecarboxylate (34)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically active compound as an oil with a molecular formula of $C_{35}H_{42}N_2O_6 \cdot 0.4 H_2O$, a molecular weight of 475.82, 1H NMR ($CDCl_3$, 300 MHz): δ 0.86-0.88 (m, 1H); 1.12-1.21 (m, 2H); 1.82-1.92 (m, 2H); 1.94-2.02 (m, 2H); 2.05-2.12 (m, 2H); 2.60 (t, 2H, $J=7.86$); 2.84 (dt, 2H, $J=7.04$); 3.33-3.35 (m, 1H); 3.46-3.48 (m, 1H); 3.75 (s, 6H); 4.58 (d, 1H, $J=6.35$); 4.97 (bs, 1H); 6.23-

6.32 (m, 2H); 7.12-7.25 (m, 6H). Thin Layer Chromatography yielded a result of $R_f = 0.65$ (90% EtOAc/hexane).

5

EXAMPLE 21

Synthesis of 3-Phenylpropyl (2S)-1-((2,4-Dimethoxyphenyl)carbamoyl)-2-pyrrolidinecarbothioate
(35)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically active compound as an oil with a molecular formula of $C_{23}H_{29}N_2O_4S$, a molecular weight of 428.57, 1H NMR ($CDCl_3$, 300 MHz): δ 1.85-1.90 (m, 2H); 2.05-2.19 (m, 4H); 2.67 (t, 2H, $J=7.52$); 2.87 (t, 2H, $J=6.61$); 3.53-3.68 (m, 1H); 3.72-3.75 (m, 1H); 3.77 (s, 3H); 3.83 (s, 3H); 4.68 (dd, 1H, $J=2.16, 8.11$); 6.43-6.46 (m, 2H); 6.80 (s, 1H); 7.14-7.19 (m, 3H); 7.24-7.28 (m, 1H); 8.06 (d, 1H, $J=7.81$). Thin Layer Chromatography yielded a result of $R_f = 0.45$ (50% EtOAc/hexane).

20

EXAMPLE 22

Synthesis of 3-Phenylpropyl (2S)-1-((1-adamantyl)carbamoyl)-2-pyrrolidinecarbothioate (36)

25

The compound was prepared in accordance with the procedures used in the above examples and

yielded an optically pure compound as a colorless oil with a molecular formula of $C_{33}H_{44}N_2O_2S$, a molecular weight of 426.64, 1H NMR ($CDCl_3$, 300 MHz): δ 1.59-1.66 (m, 6H); 1.93-2.14 (m, 14H); 2.63 (t, 2H, $J=7.57$); 2.86 (t, 2H, $J=7.23$); 3.33-3.45 (m, 1H); 4.12 (d, 2H, $J=7.12$); 4.53 (dd, 1H, $J=2.16, 8.16$); 7.12-7.29 (m, 5H). Thin Layer Chromatography yielded a result of $R_f = 0.66$ (50% EtOAc/hexane).

10

EXAMPLE 23

Synthesis of 3-Phenylpropyl (2S)-1-(1-cyclohexylcarbamoyl)-2-pyrrolidinecarboxylate (37)

The compound was prepared in accordance with the procedures used in the above examples and yielded an optically pure compound as a sticky white solid with a molecular formula of $C_{31}H_{43}N_2O_2S$, a molecular weight of 375.56, 1H NMR ($CDCl_3$, 300 MHz): δ 1.10-1.19 (m, 4H); 1.30-1.38 (m, 3H); 1.61-1.71 (m, 2H); 1.84-2.03 (m, 6H); 2.65 (t, 2H, $J=7.75$); 2.87 (t, 2H, $J=7.57$); 3.33-3.39 (m, 1H); 3.46-3.50 (m, 1H); 3.63-3.67 (m, 1H); 4.18 (d, 2H, $J=7.85$); 4.55 (dd, 1H, $J=2.14, 6.05$); 7.11-7.29 (m, 5H). Thin Layer Chromatography yielded a result of $R_f = 0.43$ (50% EtOAc/hexane).

Ki Test Procedure

Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the inventive compounds can be evaluated by known methods described in the literature (Harding, et al., *Nature*, 1989, 341:738-760; Holt et al. *J. Am. Chem. Soc.*, 115:9923-9938). These values are obtained as apparent K_i 's and are presented in Table II. The *cis-trans* isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases para-nitroanilide from the *trans* form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent K_i values.

In a plastic cuvette are added 950 μ L of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 μ L of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 μ L of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 μ L of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 μ L of substrate (succinyl-Ala-Phe-Pro-

Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in trifluoroethanol).

The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.

The data for these experiments for representative compounds are presented in Table II under the column "Ki".

The neurotrophic effects of the compounds of the present invention can be demonstrated in cellular biological experiments in vitro, as described below.

Chick Dorsal Root Ganglion

Cultures and Neurite Outgrowth

Dorsal root ganglia were dissected from chick embryos of ten day gestation. Whole ganglion explants were cultured on thin layer Matrigel-coated 12 well plates with Liebovitz L15 plus high glucose media supplemented with 2 mM glutamine and 10% fetal calf serum, and also containing 10 μ M cytosine β -D arabinofuranoside (Ara C) at 37°C in an environment containing 5% CO₂. Twenty-four hours later, the DRGs were treated with various immunophilin ligands. Forty-eight hours after drug treatment, the ganglia

were visualized under phase contrast or Hoffman Modulation contrast with a Zeiss Axiovert inverted microscope. Photomicrographs of the explants were made, and neurite outgrowth was quantitated.

5 Neurites longer than the DRG diameter were counted as positive, with total number of neurites quantitated per each experimental condition. Three to four DRGs are cultured per well, and each treatment was performed in duplicate.

10 The data for these experiments for representative compounds are presented in Table II under the column "ED₅₀".

TABLE II(a)
In Vitro Test Results

	<u>Ex. No.</u>	<u>Ki, nM</u>
5	1	+++
	2	++
	3	++
	4	++
	5	++
10	6	-
	7	++
	8	+++
	9	+++
	10	+++
15	11	++
	12	+++
	13	+++
	14	+++
	15	+++
20	16	++
	18	-
	19	*
	20	*
	21	*
25	22	+
	23	*
	24	*
	25	+
	26	*
30	27	*
	28	*
	29	*
	31	*
	32	*
35		

TABLE II(b)
In Vitro Test Results

	<u>Ex. No.</u>	<u>ED50, nM</u>
40	1	++++
	2	+++
	3	+++
	4	++
45	5	+++
	6	++
	7	+++
	8	++++
50	9	++++
	10	+++
	11	+++
	12	+++

13	++++
14	+++
15	++++
16	++

5

Table II(c): Numerical In Vitro Test Results

	<u>Ex. No.</u>	<u>Ki, nM</u>
	18	5231
10	19	10,000
	20	665
	21	795
	22	347
	23	545
15	24	605
	25	209
	26	739
	27	1494
	28	8094
20	29	5147
	31	10,000
	32	3343
	33	10,000
	34	2757
25	35	10,000
	36	235
	37	601
	38	659
	39	31
30	40	82
	41	722
	42	525
	43	3735
	44	10,000

35

†. Relative potencies of compounds are ranked according to the following scale: ++++ denotes Ki or ED50 < 1 nM; +++ denotes Ki or ED50 of 1-30 nM; ++ denotes Ki or ED 50 of 51-200 nM; + denotes Ki or ED of 201-500 nM; * denotes Ki or ED50 of > 500nM.

40

MPTP Model of Parkinson's Disease

The remarkable neurotrophic and neuroregenerative effects of the present inventive compounds can be further demonstrated in an animal model of neurodegenerative disease. MPTP lesioning of dopaminergic neurons in mice is used as an animal model of Parkinson's Disease. Four week old male CD1 white mice are dosed i.p. with 30 mg/kg of MPTP for 5 days. Test compounds (4 mg/kg), or vehicle, are administered s.c. along with the MPTP for 5 days, as well as for an additional 5 days following cessation of MPTP treatment. At 15 days following MPTP treatment, the animals are sacrificed and the striata are dissected and perfusion-fixed.

Immunostaining is performed on sagittal and coronal brain sections using anti-tyrosine hydroxylase 1 g to quantitate survival and recovery of dopaminergic neurons. In animals treated with MPTP and vehicle, a substantial loss of functional dopaminergic terminals is observed as compared to non-lesioned animals. Lesioned animals receiving test compounds show a significant recovery of TH-stained dopaminergic neurons. Data from this model presents quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving the compounds of the present invention.

Data from representative control and lesioned animals not receiving the test drugs also presents quantitation of effects in the absence of the compounds of the present invention.

5 The phrase "preventing neurodegeneration" relates to the remarkable ability of the compounds of the present invention to significantly prevent nerve damage when the compounds are given concurrently with a lesioning agent, such as MPTP.

10 This also provides a reasonable correlation between the scope of the claims and the ability to prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease, or at risk of developing a neurodegenerative disease. The


15 compounds also provide methods for preventing further neurodegeneration in patients who are already suffering from or have symptoms of a neurodegenerative disease.

 The invention being thus described, it will be

20 obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A compound of formula I:



5

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A and B are taken together with the nitrogen and carbon atoms to which they are respectively attached to form a 5-7 membered saturated or unsaturated heterocyclic ring containing any combination of CH₂, O, S, SO, SO₂, NH or NR₂;

X is either O or S;

Y is a direct bond to Z, a C₁-C₄ straight or branched chain alkyl, or a C₁-C₄ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, halcalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulphydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with C, NH,

NR₂, S, SO, or SO₂, wherein R₂ is selected from the
group consisting of hydrogen, (C₁-C₆)-straight or
branched chain alkyl, (C₁-C₆)-straight or branched
chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl
5 wherein said bridging alkyl forms a heterocyclic
ring starting with the nitrogen of NR₂ and ending
with one of the carbon atoms of said alkyl or
alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group;

10 Z is a direct bond, or a C₁-C₆ straight or
branched chain alkyl, or a C₁-C₆ straight or branched
chain alkenyl, wherein any of the carbon atoms of
said alkyl or alkenyl are optionally substituted in
one or more positions with amino, halo, haloalkyl,
15 thiocarbonyl, ester, thioester, alkoxy, alkenoxy,
cyano, nitro, imino, alkylamino, aminoalkyl,
sulfhydryl, thioalkyl, sulfonyl, oxygen to form a
carbonyl, or wherein any of the carbon atoms of said
alkyl or alkenyl are optionally replaced with O, NH,
20 NR₂, S, SO, or SO₂, wherein R₂ is selected from the
group consisting of hydrogen, (C₁-C₆)-straight or
branched chain alkyl, (C₁-C₆)-straight or branched
chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl
wherein said bridging alkyl forms a heterocyclic
25 ring starting with the nitrogen of NR₂ and ending
with one of the carbon atoms of said alkyl or

alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:

hydrogen, Ar, C₁-C₆ straight or branched chain alkyl, or C₁-C₆ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more position(s) with C₁-C₆ cycloalkyl, C₁-C₆ cycloalkenyl, hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups are optionally substituted with C₁-C₆ alkyl, C₁-C₆ alkenyl, hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₂, S, SO, or SO₂, wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₆)-straight or branched chain alkyl, (C₁-C₆)-straight or branched chain alkenyl or alkynyl, and (C₁-C₆) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of

said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

wherein Ar is an aryl or heteroaryl moiety which is substituted or unsubstituted;

W is oxygen or sulfur;

U is either O or N, wherein when U is O, then R_1 is a lone pair of electrons and R_2 is selected from the group consisting of:

Ar as defined above, C_1-C_6 cycloalkyl, C_1-C_6 straight or branched chain alkyl or alkenyl, or C_1-C_6 straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, halo, haloalkyl, hydroxy, trifluoromethyl, C_1-C_6 straight or branched chain alkyl, C_1-C_6 straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SO, SO_2 , O, or NR_2 wherein R_2 is selected from the group consisting of hydrogen, (C_1-C_6) -straight or branched chain alkyl, (C_1-C_6) -straight or branched chain alkenyl or alkynyl, and (C_1-C_6) bridging alkyl wherein said bridging alkyl forms a heterocyclic

ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or $\text{C}_1\text{-C}_6$ cycloalkyl;

5 and when U is N, R_1 and R_2 are selected independently from the group consisting of:

hydrogen, Ar as defined above, $\text{C}_1\text{-C}_6$ cycloalkyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or alkenyl, or $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, 10 halo, haloalkyl, hydroxy, trifluoromethyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, 15 imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SO, SO_2 , C, or NR_2 wherein R_2 is selected from the group 20 consisting of hydrogen, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkyl, $(\text{C}_1\text{-C}_6)$ -straight or branched chain alkenyl or alkynyl, and $(\text{C}_1\text{-C}_6)$ bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending 25 with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is

optionally fused to an Ar group or C₁-C₄ cycloalkyl;
or R₁ and R₂ may be taken together to form a
heterocyclic ring.

5 2. The compound of claim 1, wherein the mono- or
bicyclic, carbo- or heterocyclic ring is selected
from the group consisting of naphthyl, indolyl,
furyl, thiazolyl, thienyl, pyridyl, and phenyl.

10 3. The compound of claim 1, wherein the compound
has an affinity for FKBP-type immunophilins.

4. The compound of claim 3, wherein the FKBP-type
immunophilins are FKBP12.

15

5. The compound of claim 1, wherein the compound
inhibits rotamase enzyme activity.

20 6. The compound of claim 1, wherein the compound is
selected from the group consisting of:

3-Phenylpropyl (2S)-1-(1-cyclohexylcarbamoyl)-
2-pyrrolidinecarbothiate (17);

Phenethyl (2S)-N-(cyclohexylcarbamoyl)-2-
pyrrolidinecarbothiate (18);

25 3-(2,3,5-Trimethylphenyl)propyl 1-(1-
adamantylcarbamoyl)-2-pyrrolidinecarbothioate (19);

3-(2,3,5-Trimethylphenyl)propyl 1-
(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate
(20);

3-(3-Fluorophenyl)propyl (2S)-1-
5 (Cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate
(21);

3-(2-Fluorophenyl)propyl (2S)-1-(1-
adamantylcarbamoyl)-2-pyrrolidinecarbothioate (22);

3-(2-Fluorophenyl)propyl (2S)-1-
10 (cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate
(23);

3-(4-Methylphenyl)propyl (2S)-1-
(cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate
(24);

15 3-(4-Methylphenyl)propyl (2S)-1-(1-
adamantylcarbamoyl)-2-pyrrolidinecarbothioate (25);

3-(4-Methylphenyl)propyl (2S)-1-(tert-
butylcarbamoyl)-2-pyrrolidinecarbothioate (26);

3-(2-Chlorophenyl)propyl (2S)-1-
20 cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (27);

3-(3,5-Dimethoxyphenyl)propyl (2S)-1-([(1S)-1-
(1-naphthyl)ethyl]-carbamoyl)-2-
pyrrolidinecarbothioate (28);

3,3-Diphenylpropyl (2S)-1-[(1,1,3,3-
25 tetramethylbutyl)carbamoyl]-2-
pyrrolidinecarbothioate (29);

3-Cyclohexylpropyl (2S)-1-[(2,6-diisopropylphenyl)carbamoyl]-2-pyrrolidinecarbothioate (31);

5 3-Cyclohexylpropyl (2S)-1-(hexylcarbamoyl)-2-pyrrolidinecarbothioate (32);

3,3-Diphenylpropyl (2S)-1-[(2,4-dimethoxyphenyl)carbamoyl]-2-pyrrolidinecarbothioate (33);

10 3-(3,5-Dimethoxyphenyl)propyl (2S)-1-[(1S,2R)-2-phenyl-cyclopropyl]carbamoyl]-2-pyrrolidinecarbothioate (34);

3-Phenylpropyl (2S)-1-[(2,4-Dimethoxyphenyl)carbamoyl]-2-pyrrolidinecarbothioate (35);

15 3-Phenylpropyl (2S)-1-(1-adamantylcarbamoyl)-2-pyrrolidinecarbothioate (36);

3-Phenylpropyl (2S)-1-(1-cyclohexylcarbamoyl)-2-pyrrolidinecarbothioate (37);

20 3-Phenylpropyl (2S)-1-[1-adamantylamino(thioxo)-methyl]-2-pyrrolidinecarbothioate (38);

3-(3,4,5-Trimethoxyphenyl)propyl (2S)-1-(hexylcarbamoyl)-2-pyrrolidinecarbothioate (39);

3-(3,4,5-Trimethoxyphenyl)propyl (2S)-1-(benzylcarbamoyl)-2-pyrrolidinecarbothioate (40);

25 3-Phenylpropyl (2S)-1-(dimethylcarbamoyl)-2-pyrrolidinecarbothioate (41);

3-Phenylpropyl (2S)-1-(1-pyrrolidinylcarbonyl)-
2-pyrrolidinecarbothioate (42);

3-Phenylpropyl (2S)-1-(morpholinecarbonyl)-2-
pyrrolidinecarbothioate (43);

5 3-Phenylpropyl (2S)-1-(diisopropylcarbamoyl)-2-
pyrrolidinecarbothioate (44);

3-Phenylpropyl (2S)-1-
[methyl(phenyl)carbamoyl]-2-pyrrolidinecarbothioate
(45); and

10 3-Phenylpropyl (2S)-1-(diphenylcarbamoyl)-2-
pyrrolidinecarbothioate (46).

7. A pharmaceutical composition comprising a
15 neurotrophically effective amount of the compound of
claim 1 and a pharmaceutically acceptable carrier.

8. A method of effecting a neuronal activity in an
animal, comprising:

20 administering to the animal a neurotrophically
effective amount of the compound of claim 1.


9. The method of claim 8, wherein the neuronal
activity is selected from the group consisting of
25 stimulation of damaged neurons, promotion of
neuronal regeneration, prevention of

neurodegeneration and treatment of neurological disorder.

10. The method of claim 9, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

11. The method of claim 10, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

12. A compound of formula II:



II

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

E, F, G and H are independently CH_3 , C, S, SO_2 , SO_2 , NH or NR, wherein at least two of E, F, G, and H are CH_3 ;

X is either O or S;

5 Y is a direct bond to E, a C_1 - C_6 straight or branched chain alkyl, or a C_1 - C_6 straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, 10 thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, 15 NR_1 , S, SO, or SO_2 , wherein R_1 is selected from the group consisting of hydrogen, $(\text{C}_1$ - C_6)-straight or branched chain alkyl, $(\text{C}_1$ - C_6)-straight or branched chain alkenyl or alkynyl, and $(\text{C}_1$ - C_6) bridging alkyl wherein said bridging alkyl forms a heterocyclic 20 ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

25 Z is a direct bond, or a C_1 - C_6 straight or branched chain alkyl, or a C_1 - C_6 straight or branched chain alkenyl, wherein any of the carbon atoms of

said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, 5 sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or 10 branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or 15 alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:

hydrogen, Ar, C₁-C₄ straight or branched chain alkyl, or C₁-C₄ straight or branched chain alkenyl, 20 wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more position(s) with C₁-C₄ cycloalkyl, C₁-C₄ cycloalkenyl, hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups 25 are optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, hydroxy, amino, halo, haloalkyl,

thiocarbonyl, ester, thioester, alkoxy, alkenoxy,
cyano, nitro, imino, alkylamino, aminoalkyl,
sulfhydryl, thioalkyl, sulfonyl, wherein any of the
carbon atoms of said alkyl or alkenyl are optionally
5 substituted in one or more positions with oxygen to
form a carbonyl, or wherein any of the carbon atoms
of said alkyl or alkenyl are optionally replaced
with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is
selected from the group consisting of hydrogen, (C₁-
10 C₃)-straight or branched chain alkyl, (C₁-C₃)-
straight or branched chain alkenyl or alkynyl, and
(C₁-C₃) bridging alkyl wherein said bridging alkyl
forms a heterocyclic ring starting with the nitrogen
of NR₁ and ending with one of the carbon atoms of
15 said alkyl or alkenyl chain, and wherein said
heterocyclic ring is optionally fused to an Ar
group;

wherein Ar is an aryl or heterocaryl moiety
which is substituted or unsubstituted;

20 W is oxygen or sulfur;

U is either O or N, wherein when U is O, then
R₁ is a lone pair of electrons and R₂ is selected
from the group consisting of:

Ar as defined above, C₁-C₃ cycloalkyl, C₁-C₃
25 straight or branched chain alkyl or alkenyl, or C₁-C₃
straight or branched chain alkyl or alkenyl

substituted in one or more positions with Ar, amino,
halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₆,
straight or branched chain alkyl, C₁-C₆, straight or
branched chain alkenyl, carbonyl, thiocarbonyl,
5 ester, thioester, alkoxy, alkenoxy, cyano, nitro,
imino, alkylamino, aminoalkyl, sulfhydryl,
thioalkyl, sulfonyl, substituted alkyl or alkenyl
wherein any of the carbon atoms of the alkyl or
alkenyl are optionally replaced with S, SO, SO₂, O,
10 or NR₂ wherein R₂ is selected from the group
consisting of hydrogen, (C₁-C₆)-straight or branched
chain alkyl, (C₁-C₆)-straight or branched chain
alkenyl or alkynyl, and (C₁-C₆) bridging alkyl
wherein said bridging alkyl forms a heterocyclic
15 ring starting with the nitrogen of NR₂ and ending
with one of the carbon atoms of said alkyl or
alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group or C₁-C₆ cycloalkyl;

and when U is N, R₁ and R₂ are selected
20 independently from the group consisting of:
hydrogen, Ar as defined above, C₁-C₆ cycloalkyl,
C₁-C₆, straight or branched chain alkyl or alkenyl, or
C₁-C₆, straight or branched chain alkyl or alkenyl
substituted in one or more positions with Ar, amino,
25 halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₆,
straight or branched chain alkyl, C₁-C₆, straight or

branched chain alkenyl, carbonyl, thiocarbonyl,
ester, thioester, alkoxy, alkenoxy, cyano, nitro,
imino, alkylamino, aminoalkyl, sulfhydryl,
thioalkyl, sulfonyl, substituted alkyl or alkenyl
5 wherein any of the carbon atoms of the alkyl or
alkenyl are optionally replaced with S, SO, SO₂, O,
or NR₁ wherein R₁ is selected from the group
consisting of hydrogen, (C₁-C₄)-straight or branched
chain alkyl, (C₁-C₃)-straight or branched chain
10 alkenyl or alkynyl, and (C₁-C₄) bridging alkyl
wherein said bridging alkyl forms a heterocyclic
ring starting with the nitrogen of NR₁ and ending
with one of the carbon atoms of said alkyl or
alkenyl chain, and wherein said heterocyclic ring is
15 optionally fused to an Ar group or C₃-C₆ cycloalkyl;
or R₁ and R₂ may be taken together to form a
heterocyclic ring.

13. The compound of claim 12, wherein Ar is
20 selected from the group consisting of naphthyl,
indolyl, furyl, thiazolyl, thienyl, pyridyl, and
phenyl.

14. The compound of claim 12, wherein the compound
25 has an affinity for FKBP-type immunophilins.

15. The compound of claim 14, wherein the FKBP-type immunophilins are FKBP12.

16. The compound of claim 12, wherein the compound
5 inhibits rotamase enzyme activity.

17. A pharmaceutical composition comprising a
neurotrophically effective amount of the compound of
claim 12 and a pharmaceutically acceptable carrier.

10

18. A method of effecting a neuronal activity in an
animal, comprising:

administering to the animal a neurotrophically
effective amount of the compound of claim 12.

15


19. The method of claim 18, wherein the neuronal
activity is selected from the group consisting of
stimulation of damaged neurons, promotion of
neuronal regeneration, prevention of
20 neurodegeneration and treatment of neurological
disorder.

20. The method of claim 19, wherein the
neurological disorder is selected from the group
consisting of peripheral neuropathy caused by
25 physical injury or disease state, physical damage to

the brain, physical damage to the spinal cord,
stroke associated with brain damage, and
neurological disorder relating to neurodegeneration.

- 5 21. The method of claim 20, wherein the
neurological disorder relating to neurodegeneration
is selected from the group consisting of Alzheimer's
Disease, Parkinson's Disease, and amyotrophic
lateral sclerosis.

22. A compound of formula III:



5 or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

E, F, and G are independently CH₂, O, S, SO, SO₂, NH or NR₁, wherein at least 2 of E, F, and G are CH₂;

10 X is either O or S;

Y is a direct bond to Z, a C₁-C₆ straight or branched chain alkyl, or a C₁-C₆ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₆)-straight or branched chain alkyl, (C₁-C₆)-straight or branched chain alkenyl or alkynyl, and (C₁-C₆) bridging alkyl

wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

Z is a direct bond, or a C_1-C_6 straight or branched chain alkyl, or a C_1-C_6 straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR_2 , S, SO, or SO_2 , wherein R_2 is selected from the group consisting of hydrogen, (C_1-C_6) -straight or branched chain alkyl, (C_1-C_6) -straight or branched chain alkenyl or alkynyl, and (C_1-C_6) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR_1 and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:
hydrogen, Ar, C_1-C_6 straight or branched chain

alkyl, or C₁-C₄ straight or branched chain alkenyl,..
wherein any of the carbon atoms of said alkyl or
alkenyl are optionally substituted in one or more
position(s) with C₁-C₄ cycloalkyl, C₁-C₄ cycloalkenyl,
5 hydroxyl, carbonyl oxygen, or Ar, wherein said
alkyl, alkenyl, cycloalkyl or cycloalkenyl groups
are optionally substituted with C₁-C₄ alkyl, C₁-C₄
alkenyl, hydroxy, amino, halo, haloalkyl,
thiocarbonyl, ester, thioester, alkoxy, alkenoxy,
10 cyano, nitro, imino, alkylamino, aminoalkyl,
sulfhydryl, thioalkyl, sulfonyl, wherein any of the
carbon atoms of said alkyl or alkenyl are optionally
substituted in one or more positions with oxygen to
form a carbonyl, or wherein any of the carbon atoms
15 of said alkyl or alkenyl are optionally replaced
with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is
selected from the group consisting of hydrogen, (C₁-
C₄)-straight or branched chain alkyl, (C₁-C₄)-
straight or branched chain alkenyl or alkynyl, and
20 (C₁-C₄) bridging alkyl wherein said bridging alkyl
forms a heterocyclic ring starting with the nitrogen
of NR₁ and ending with one of the carbon atoms of
said alkyl or alkenyl chain, and wherein said
heterocyclic ring is optionally fused to an Ar
25 group;

wherein Ar is an aryl or heteroaryl moiety

which is substituted or unsubstituted;

W is oxygen or sulfur;

U is either O or N, wherein when U is C, then

R₁ is a lone pair of electrons and R₂ is selected

5 from the group consisting of:

Ar as defined above, C₁-C₆ cycloalkyl, C₁-C₆,
straight or branched chain alkyl or alkenyl, or C₁-C₆,
straight or branched chain alkyl or alkenyl
substituted in one or more positions with Ar, amino,
10 halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₆,
straight or branched chain alkyl, C₁-C₆ straight or
branched chain alkenyl, carbonyl, thiocarbonyl,
ester, thioester, alkoxy, alkenoxy, cyano, nitro,
imino, alkylamino, aminoalkyl, sulfhydryl,
15 thioalkyl, sulfonyl, substituted alkyl or alkenyl
wherein any of the carbon atoms of the alkyl or
alkenyl are optionally replaced with S, SO, SO₂, O,
or NR₂ wherein R₂ is selected from the group
consisting of hydrogen, (C₁-C₆)-straight or branched
20 chain alkyl, (C₁-C₆)-straight or branched chain
alkenyl or alkynyl, and (C₁-C₆) bridging alkyl
wherein said bridging alkyl forms a heterocyclic
ring starting with the nitrogen of NR₂ and ending
with one of the carbon atoms of said alkyl or
25 alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group or C₁-C₆ cycloalkyl;

and when U is N, R₁ and R₂ are selected independently from the group consisting of:

hydrogen, Ar as defined above, C₁-C₄ cycloalkyl, C₁-C₄ straight or branched chain alkyl or alkenyl, or C₁-C₄ straight or branched chain alkyl or alkenyl substituted in one or more positions with Ar, amino, halo, haloalkyl, hydroxy, trifluoromethyl, C₁-C₄ straight or branched chain alkyl, C₁-C₄ straight or branched chain alkenyl, carbonyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, substituted alkyl or alkenyl wherein any of the carbon atoms of the alkyl or alkenyl are optionally replaced with S, SO, SO₂, O, or NR₂ wherein R₂ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₂ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group or C₁-C₄ cycloalkyl; or R₁ and R₂ may be taken together to form a heterocyclic ring.

23. The compound of claim 22, wherein Ar is selected from the group consisting of naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, and phenyl.

5

24. The compound of claim 22, wherein the compound has an affinity for FKBP-type immunophilins.

25. The compound of claim 24, wherein the FKBP-type immunophilins are FKBP12.

10

26. The compound of claim 22, wherein the compound inhibits rotamase enzyme activity.

27. A pharmaceutical composition comprising a neurotrophically effective amount of the compound of claim 22 and a pharmaceutically acceptable carrier.

15

28. A method of effecting a neuronal activity in an animal, comprising:

20

administering to the animal a neurotrophically effective amount of the compound of claim 22.

29. The method of claim 28, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of


25

neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

5 30. The method of claim 29, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord,
10 stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

31. The method of claim 30, wherein the neurological disorder relating to neurodegeneration
15 is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

32. A compound of formula IV:



or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

n is 1, 2 or 3 forming a 5-7 member heterocyclic ring;

X is either O or S;

Y is a direct bond to Z, a C₁-C₆ straight or
5 branched chain alkyl, or a C₁-C₆ straight or branched
chain alkenyl, wherein any of the carbon atoms of
said alkyl or alkenyl are optionally substituted in
one or more positions with amino, halo, haloalkyl,
thiocarbonyl, ester, thioester, alkoxy, alkenoxy,
10 cyano, nitro, imino, alkylamino, aminoalkyl,
sulfhydryl, thioalkyl, sulfonyl, oxygen to form a
carbonyl, or wherein any of the carbon atoms of said
alkyl or alkenyl are optionally replaced with O, NH,
NR₂, S, SO, or SO₂, wherein R₂ is selected from the
15 group consisting of hydrogen, (C₁-C₆)-straight or
branched chain alkyl, (C₁-C₆)-straight or branched
chain alkenyl or alkynyl, and (C₁-C₆) bridging alkyl
wherein said bridging alkyl forms a heterocyclic
ring starting with the nitrogen of NR₂ and ending
20 with one of the carbon atoms of said alkyl or
alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group;

Z is a direct bond, or a C₁-C₆ straight or
branched chain alkyl, or a C₁-C₆ straight or branched
25 chain alkenyl, wherein any of the carbon atoms of
said alkyl or alkenyl are optionally substituted in

one or more positions with amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, oxygen to form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₄)-straight or branched chain alkyl, (C₁-C₄)-straight or branched chain alkenyl or alkynyl, and (C₁-C₄) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said heterocyclic ring is optionally fused to an Ar group;

C and D are independently:

hydrogen, Ar, C₁-C₄ straight or branched chain alkyl, or C₁-C₄ straight or branched chain alkenyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more position(s) with C₁-C₄ cycloalkyl, C₁-C₄ cycloalkenyl, hydroxyl, carbonyl oxygen, or Ar, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups are optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, hydroxy, amino, halo, haloalkyl, thiocarbonyl, ester, thioester, alkoxy, alkenoxy,

cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, sulfonyl, wherein any of the carbon atoms of said alkyl or alkenyl are optionally substituted in one or more positions with oxygen to
5 form a carbonyl, or wherein any of the carbon atoms of said alkyl or alkenyl are optionally replaced with O, NH, NR₁, S, SO, or SO₂, wherein R₁ is selected from the group consisting of hydrogen, (C₁-C₆)-straight or branched chain alkyl, (C₃-C₆)-
10 straight or branched chain alkenyl or alkynyl, and (C₁-C₆) bridging alkyl wherein said bridging alkyl forms a heterocyclic ring starting with the nitrogen of NR₁ and ending with one of the carbon atoms of said alkyl or alkenyl chain, and wherein said
15 heterocyclic ring is optionally fused to an Ar group;

wherein Ar is an aryl or heteroaryl moiety which is substituted or unsubstituted;

W is oxygen or sulfur;

20 U is either O or N, wherein when U is O, then R₁ is a lone pair of electrons and R₂ is selected from the group consisting of:

Ar as defined above, C₃-C₆ cycloalkyl, C₁-C₆ straight or branched chain alkyl or alkenyl, or C₁-C₆ straight or branched chain alkyl or alkenyl
25 substituted in one or more positions with Ar, amino,

halo, haloalkyl, hydroxy, trifluoromethyl, C_1-C_6 ,
straight or branched chain alkyl, C_1-C_6 , straight or
branched chain alkenyl, carbonyl, thiocarbonyl,
ester, thioester, alkoxy, alkenoxy, cyano, nitro,
5 imino, alkylamino, aminoalkyl, sulfhydryl,
thioalkyl, sulfonyl, substituted alkyl or alkenyl
wherein any of the carbon atoms of the alkyl or
alkenyl are optionally replaced with S, SO, SO_2 , O,
or NR_1 wherein R_1 is selected from the group
10 consisting of hydrogen, (C_1-C_6) -straight or branched
chain alkyl, (C_1-C_6) -straight or branched chain
alkenyl or alkynyl, and (C_1-C_6) bridging alkyl
wherein said bridging alkyl forms a heterocyclic
ring starting with the nitrogen of NR_1 and ending
15 with one of the carbon atoms of said alkyl or
alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group or C_1-C_6 cycloalkyl;
and when U is N, R_1 and R_2 are selected
independently from the group consisting of:
20 hydrogen, Ar as defined above, C_1-C_6 cycloalkyl,
 C_1-C_6 , straight or branched chain alkyl or alkenyl, or
 C_1-C_6 , straight or branched chain alkyl or alkenyl
substituted in one or more positions with Ar, amino,
halo, haloalkyl, hydroxy, trifluoromethyl, C_1-C_6 ,
25 straight or branched chain alkyl, C_1-C_6 , straight or
branched chain alkenyl, carbonyl, thiocarbonyl,

ester, thioester, alkoxy, alkenoxy, cyano, nitro,
imino, alkylamino, aminoalkyl, sulfhydryl,
thioalkyl, sulfonyl, substituted alkyl or alkenyl
wherein any of the carbon atoms of the alkyl or
5 alkenyl are optionally replaced with S, SO, SO₂, O,
or NR₂ wherein R₂ is selected from the group
consisting of hydrogen, (C₁-C₄)-straight or branched
chain alkyl, (C₁-C₄)-straight or branched chain
alkenyl or alkynyl, and (C₁-C₄) bridging alkyl
10 wherein said bridging alkyl forms a heterocyclic
ring starting with the nitrogen of NR₂ and ending
with one of the carbon atoms of said alkyl or
alkenyl chain, and wherein said heterocyclic ring is
optionally fused to an Ar group or C₁-C₄ cycloalkyl;
15 or R₁ and R₂ may be taken together to form a
heterocyclic ring.

33. The compound of claim 32, wherein Ar is
selected from the group consisting of naphthyl,
20 indolyl, furyl, thiazolyl, thienyl, pyridyl, and
phenyl.

34. The compound of claim 32, wherein the compound
has an affinity for FKBP-type immunophilins.

25

35. The compound of claim 34, wherein the FKBP-type

immunophilins are FKBP12.

36. The compound of claim 32, wherein the compound inhibits rotamase enzyme activity.

5

37. A pharmaceutical composition comprising a neurotrophically effective amount of the compound of claim 32 and a pharmaceutically acceptable carrier.

10 38. A method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of the compound of claim 32.

15 39. The method of claim 38, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological
20 disorder.

40. The method of claim 39, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by
25 physical injury or disease state, physical damage to the brain, physical damage to the spinal cord,

stroke associated with brain damage, and
neurological disorder relating to neurodegeneration.

41. The method of claim 40, wherein the
5 neurological disorder relating to neurodegeneration
is selected from the group consisting of Alzheimer's
Disease, Parkinson's Disease, and amyotrophic
lateral sclerosis.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/24070

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/40; C07D 207/08, 207/12

US CL : 514/423, 428; 548/531, 536

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/423, 428; 548/531, 536

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, MEDLINE, BIOSIS

search terms: FKBP?, rotamase?, inhibit?, innumophilin?, thioester?, carbamat?, urea?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,330,993A (ARMISTEAD et al.) 19 July 1994, see entire document.	1-41
Y	US 5,516,797 A (ARMISTEAD et al.) 14 May 1996, see entire document.	1-41
A	SOMERS, et al. Synthesis and Analysis of 506BD, a High-Affinity Ligand for the Innumophilin FKBP. J. Am. Chem. Soc. 09 October 1991, Vol.113, No.21, pages 8045-8056, especially pages 8045-8050.	1-6, 12-16, 22-26, 32-36.

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 MARCH 1998

Date of mailing of the international search report

10 APR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANE C. OSWECKI

Telephone No. (703) 308-1235

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-41 in part

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

The following table defines the inventions claimed in this application. By selecting a variable from each heading, one can arrive at 256 individual groups:

A, B

pyrrolidinyl
pyridyl
pyrimidyl
oxazole or thiazole

*R₁, R₂

H or non-heterocycle
hydrocarbyl
pyridyl or pyrimidyl

Y

direct bond or aliphatic hydrocarbyl
NR₁-alkyl or -alkenyl ring

Z

H, bond, aliphatic hydrocarbyl
NR₁-alkyl or -alkenyl ring

U

oxygen
nitrogen

*Note: proviso that when U is oxygen, R₁ is a lone electron pair.

A sample selection of three (3) individual groups is given below:

Group I, claims 1, 12, 22 and 32, drawn to compounds of formulae I-IV wherein A and B together form pyrrolidine, R₁ is an electron pair, R₂ is hydrogen, C and D are each hydrogen, Y and Z are each a direct bond and U is oxygen. (This is the compound the examiner considers to be the first claimed invention).

Group II, claims 1, 12, 22 and 32, drawn to compounds of formulae I-IV wherein A and B together form pyridine, R₁ is an electron pair, R₂ is hydrogen, C and D are each hydrogen, Y and Z are each a direct bond and U is oxygen.

Group CCLVI, claims 1, 12, 22 and 32, drawn to compounds of formulae I-IV wherein A and B together form oxazole or thiazole, R₁ and R₂ together form pyrimidyl, C is an NR₁-alkyl or

-alkenyl ring, D is an NR₁-alkyl or -alkenyl ring, Y is an NR₁-alkyl or -alkenyl ring, Z is an NR₁-alkyl or -alkenyl ring and U is nitrogen.

Claims 2-11, 13-21, 23-31 and 32-41 will be examined as commensurate in scope with the group elected.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/24070

The inventions listed as Groups I-CCLVI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: no special technical feature which makes a contribution over the prior art exists within the structures depicted in formulae I-IV in claims 1, 12, 22 and 32. The only structural constants shown are -N-C-C-S- which appear in claim 1 on an otherwise completely variable chain. Nitrogen and sulfur are both known elements. Any contribution over the prior art must, therefore, reside in the possibilities for the various substituents and combinations thereof, which render the compounds different from one another; as such, they are not known as equivalents in the art.

